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ABSTRACT

Infectious diseases are an increasing threat to shrimp farming industries
worldwide and account for nearly $3 billion of annual economic loss. The need to devise
novel approaches against these infectious agents is pressing, as traditional methods are
insufficient to ward off infections. The main aim of this study was to apply
paratransgenesis to control infectious agents mediating shrimp diseases. As proof-ofconcept we showed that Artemia, a food source in shrimp aquaculture, internalized
bacteria expressing recombinant proteins. Stable expression and retention of these marker
molecules up to 10 hours after feeding with the transgenic bacteria were evident within
the gut of Artemia, coincident with the time period of highest density of internalized
microorganisms. Uptake of recombinant proteins by Artemia occurred during active
feeding, with their rapid depletion during a non-feeding washout phase. Bioamplification
of recombinant proteins through increasing trophic levels via the paratransgenic approach
was then tested. For this trials were conducted aimed at delivery of recombinant proteins
vii

to larval stages of the commercial white shrimp, Litopenaeus vannamei, via direct
feeding of transgenic bacteria or via feeding transgenic bacteria-engorged Artemia. In
both trials, shrimp extracts showed recombinant protein accumulation during the active
feeding phase and decrease during the washout period. From these studies we concluded
that transgenic expression of proteins in bacteria can be detected through their
paratransgenic expression in Artemia and shrimp, suggesting that this commonly
employed feed organism could be applied to target infectious agents in shrimp
mariculture. For this purpose we identified cecropin and melittin as effective
antimicrobial peptides against vibrio species, and their combination was particularly
potent without toxicity toward probiotic bacteria or algal feed organisms. Furthermore,
unlike mellitin alone antibiotic resistance did not develop in Vibrio strains exposed to the
cecropin/melittin mixture. Finally, the melittin gene was transduced into B.subtilis, and
expression of significant levels of melittin was detected, although this was insufficient to
cause detectable anti-vibrio activity. Optimization of B.subtilis expression for higher
antimicrobial peptide production or employment of algal strains for anti-infectious
molecule expression are key future directions for developing a paratransgenic approach
as an environmentally sustainable disease mitigation strategy in marine aquaculture.
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CHAPTER 1
GENERAL INTRODUCTION AND MAJOR AIMS OF DISSERTATION
This chapter is adapted from the following published article:
Durvasula, R., Subhadra, B., Matthews, S., Hurwitz, I., Subba Rao, D.V., 2009.
Paratransgenic approaches to the control of infections of shrimp: Prospects for use of
Dunaliella Pp. 385-402. In: Ben Amotz, A., Polle, A.E.W., Subba Rao, D.V. (Eds). The
Alga Dunaliella: Biodiversity, Physiology, Genomics and Biotechnology. Science
Publishers, New Hampshire, USA.
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AQUACULUTURE
Aquaculture is the fastest growing food sector globally and holds great promise
for closing the nutritional gap for many of the world‟s population (Smith et al., 2010).
Further, aquaculture-based animal production system has several advantages over other
animal protein production systems (Table 1). World aquaculture production has
increased to 59.4 million metric tons (MT) in 2008, with a value of $70 billion. While
total production from capture fisheries is now declining, aquaculture, in contrast, has
increased by ~9 percent per year since 1985 and now accounts for about half of all
aquatic harvest by weight (SOFIA, 2008). Of this, farmed shrimp production accounts for
2.4 million MT, representing a value of nearly $10 billion (FAO, 2009). The intensive
aquaculture has also several sustainability issues associated with it (Naylor et al., 2000).
The reliance on use of wild-caught fish in aquaculture feeds, which could deplete food
supplies for other marine life and the aquaculture industry itself over time, is a major
sustainability issue (Aquaculture Task Force, 2007; Naylor et al., 2009). Emergence of
drug-resistant bacteria due to indiscriminate use of antibiotics in aquafeed for disease
control and growth promotion has also been a major public health issue related to
sustainability of mariculture. The use of coastal and marine resources for aquaculture
poses environmental threats including spread of disease from farmed to wild fish and
nutrient discharge of effluents into surrounding waters (i.e. eutrophication).
The aquaculture industry‟s growth in the US has been less pronounced but just as
steady as global production (Goldburg et al., 2001). Instead of depending largely on fishfarming to meet demand, the US has relied on high levels of seafood imports.
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Table 1. Comparison of fish and shellfish meat production with other terrestrial meat
production systems (Deutch et al., 2007).
Production
FCR1
LUE2
CF3
HBI 4
System
Beef
9.0
45.0
14.0
1
Pork
3.5
873.0
4.8
1
Poultry
2.0
7946.0
1.8
2
Fish/Shellfish
1.8
7941.0
2.0
3
1
Food Conversion Ratio - Kg of feed required to produce/ kg of meat;
2
Land Use Efficeincy - Kg/ha/year;
3
Carbon Footprint - KgCO2-e/Kg;
4
Health Benefit Index- An index based on availability, digestability and health
benefits of nutrients such as protein, lipid, micronutrients, vitamins . 1 = good ; 2 =
very good; 3 = excellent.
In the US, one of the world‟s fastest-growing seafood markets, the gap between
demand and supply is even more pronounced, contributing in excess of $8 billion seafood
trade deficit. About half of the trade deficit is in shrimp. Per capita consumption of
seafood in the U.S. has jumped to 16.3 pounds, its highest level in more than 20 years,
and is expected to continue rising. America‟s aquaculture industry currently meets only a
meager 5-7% of domestic demand for seafood. Generally, more and more consumers are
recognizing fish and shellfish as an excellent source of high-quality protein, containing
lipids with high levels of health-promoting omega-3 fatty acids (Lee et al., 2009), which
are increasing the demand of seafood. The US saw a rapid growth in its elderly
population during the 20th century. The number of Americans aged 65 and older climbed
above 34.9 million in 2000, compared to 3.1 million in 1900. Between 1990 and 2020,
the population aged 65 to 74 is projected to grow 74% (US Bureau of Census, 2008). The
elderly populations are consumers of seafood because of the health benefits of fish on
many degenerative diseases and enhancement of health by reducing the risk of
cardiovascular diseases. The growing elderly population will add an additional demand
3

for seafood in the coming decades suggesting the crucial need for local production and
marketing of seafood.
INFECTIOUS DISEASE PROBLEMS IN AQUACULTURE
Becaue of the increased demand of seafood production the production practices in
aquaculture industry were oriented towards high intensity production method. This
method includes heavy stocking and high level of feeding. This is especially true for the
production of shrimp as land and water suitable for shrimp production are limited and
confined to coastal areas. The heavy nutrient content (e.g. high organic load) of the water,
high biological carrying capacity of culture water and reduced water quality (e.g. high
ammonia and less oxygen) of culture water are physiological stress factors and immune
compromise factors for shrimp. These physiological conditions of culture shrimp caused
the emergence of numerous infectious diseases in shrimp. Diseases caused by agents such
as White Spot Syndrome Virus (WSSV) and Vibrio species have decimated shrimp
farming industries in many parts of Asia and South America, and account for nearly $3
billion of economic loss annually. Unregulated uses of antibiotics in farmed shrimp and
fish operations have widely been banned and contribute to the epidemic of drug-resistant
bacteria in humans. Intensive practices that involve meticulous water exchange with strict
standards of hygiene have been effective in reducing transmission of infectious pathogens
in farmed shrimp (Otoshi et al., 2002; Otoshi et al., 2001) but are impractical in many
lower-income settings of the world. Usually, appearance of disease is associated with loss
of harvest for shrimp farmers and a staggering 30% of global production is lost annually.
The economic impact of infectious diseases of mariculture is overshadowed only by their
tremendous threat to global food security.
4

WHITE SPOT SYNDROME VIRUS
WSSV is the most striking example of shrimp viral disease. This disease has
devastated many parts of the world with grave economic consequences and reduction in
available food supply. Infection of peneaid shrimp by WSSV can result in up to 100%
mortality within 3 to 7 days. The virus is extremely virulent and has a broad host range
including other marine invertebrates such as crayfish and crab. The global annual
economic loss due to WSSV is estimated to be $3 billion (Hill, 2005). In much of the
world, there is no effective method to control this disease. Entry and pathogenesis of
WSSV in peneaid shrimp occur either via oral ingestion or water-borne contact (Chou et
al., 1998). Work by several investigators has demonstrated that VP28, a structural protein
found on the virion envelope, is responsible for viral attachment, penetration and
consequently the systemic infection of shrimp (Chappel et al., 2004; van Hulten et al.,
2001). Although studies on the shrimp immune response are limited, the presence of viral
inhibiting proteins in both experimental and natural survivors of WSSV infections
suggests that a primitive adaptive immune-like response called „quasi-immune‟ response
exists in shrimp (Venegas et al., 2000; Wu et al., 2002). In crustacea, the lymphoid organ
(LO) is found exclusively in penaeid prawns and believed that the lymphoid organ is
involved in defence against invading pathogens. The discovery of immune-related genes
with the LO confirms some cells have immunological roles even though these genes
might be from the haemocytes within this organ. The formation of the lymphoid organ
spheroid (LOS) cells has been observed in many naturally or experimentally infected
penaeid prawns with viral diseases. It has been suggested that these spheroid cells
constitute a major site of viral degradation and is most likely that this cell type is
5

produced from exocytosed granular haemocytes and eliminated to the environment rather
than in situ destruction via necrosis or apoptosis (Owens, 2010).
Venegas et al. (Venegas et al., 2000) were the first to report that Kuruma shrimp
(Penaeus japonicas) survivors from WSSV outbreaks were able to survive a subsequent
WSSV challenge with very little mortality when compared to naïve control shrimp. This
was later shown to be associated with WSSV neutralizing activity in the shrimp
hemolymph (Wu et al., 2002) although specificity was not tested using a different virus,
for example. Other reports have shown that administration of inactivated WSSV (Bright
Singh et al., 2005) or heterologously expressed WSSV coat proteins by either injection or
feeding can give some protection against mortality from a subsequent WSSV challenge
(Namikoshi et al., 2004; Witteveldt et al., 2004; Xu et al., 2006). Although these reports
refer to the process as “vaccination,” that designation may be inappropriate, since the
underlying mechanisms have not been elucidated and shrimp are not known to possess
antibodies. Several approaches using VP28 and another structural envelope protein,
VP19, have been used to elicit an immune response in shrimp. Witteveldt et al. (2004)
orally vaccinated P. monodon and L. vannamei (Witteveldt et al., 2006), two of the most
important cultured shrimp species, using feed pellets coated with inactivated bacteria that
were over-expressing VP28. In both cases, lower mortality was found in test versus
control animals up to three weeks post vaccination. In a similar study, crayfish were
protected fully from WSSV following injection with fusion VP19 + VP28 polyclonal
antiserum (Li et al., 2005). Vaccination trials with VP292, a newly identified envelope
protein, also resulted in significant resistance to WSSV for up to 30 days post initial
vaccination (Vaseeharan et al., 2006). Using a different strategy, Robalino et al. (2005,
6

2007) demonstrated that the administration of dsRNA specific for WSSV genes induces a
potent and virus-specific antiviral response in shrimp. Both studies revealed significant
reduction in mortality in the shrimp population protected by vp28 and vp19 dsRNA
injections.
These approaches to controlling WSSV involve induction of an immune response
to virulence epitopes of WSSV and suggest that this could potentially control this disease.
In each approach, however, vaccine delivery constrains implementation. The method
used in the studies cited above, individual inoculation of shrimp, is highly impractical
under field conditions. Given that a typical shrimp grow-out pond can harbor upwards of
300,000 post-larvae per hectare, labor costs imposed by this method rule out commercial
application. The coating of dry feed with inoculum appears logical, but the feeding
behavior of shrimp involves the slow nibbling of feed particles. This sluggish behavior
can cause substantial losses of inoculum through leaching. It has been demonstrated that
within an hour, shrimp feed can lose more than 20% of its crude protein, about 50% of its
carbohydrates and 85 to 95% of its vitamin content (Rosenberry, 2005). In light of the
tremendous global impact of WSSV on shrimp farming and the constraints of highintensity cultivation, new strategies to impart immunity against WSSV are essential. It is
also critical that such a technology be economically viable, scalable to large shrimp
farming facilities and be easily delivered to the shrimp.
VIBRIOSIS
Vibriosis is one of the most devastating bacterial diseases caused by at least 14
species of Vibrio (Brock and Lightner, 1990). Highly virulent strains such as V. harveyi,
V. vulnificus, V. penaeicida, V. parahaemolyticus, V. alginolyticus and V.
7

nigripulchritudo can cause up to 90% mortality within a day after infection in Penaeus
monodon, P. japonicus and L. vannamei (Lavilla-Pitago et al., 1998). The term Vibriosis
describes a spectrum of diseases and includes oral and enteric Vibriosis, appendage and
cuticular Vibriosis, localized Vibriosis of wounds, shell disease, systemic Vibriosis and
septic hepatopancreatitis (Brock and Lightner, 1990). Outbreaks may occur when
environmental factors trigger the rapid multiplication of bacteria usually tolerated at low
levels within shrimp blood (Sizemore and Davis, 1985), or by bacterial penetration of
host barriers. The shrimp exoskeleton provides an effective physical barrier to pathogens,
however, Vibrio spp. are chitinoclastic bacteria associated with shell disease and may
enter through wounds in the exoskeleton or pores (Jiravanichpaisal and Miyazaki, 1994;
Alday-Sanz et al., 2002). In recent years, Vibriosis caused by V. nigripulchritudo and V.
penaeicida caused enormous losses in various shrimp grow-out facilities in New
Caledonia (Reynaud et al., 2008; Sakai et al., 2007; Goarant et al., 2006). Many new
techniques have been proposed for the control of Vibriosis but most of them are
impractical and are not cost-effective under field conditions. The lack of a vertebrate –
like adaptive immune response mediated by B and T cells limits the use of vibrio-specific
vaccination strategies in shrimp (Hill, 2005). Use of prophylatic antibiotics in aquaculture
is banned in many countries due to emergence of antibiotic-resistant microbes (Cabello,
2006; FAO-WHO, 2006). Emergence of novel, drug resistant forms of these pathogens
compounds the crisis for many shrimp farmers. The need for new tools in the battle
against Vibriosis is pressing.
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USE OF PROBIOTICS IN AQUACULTURE
Probiotics are defined as microorganisms that are beneficial to the health of the
host. They are not therapeutic agents but, instead, directly or indirectly alter the
composition of the microbial community in the rearing environment or in the gut of the
host. Although the mode of action of probiotics is not fully understood, it is likely that
they function by competitive exclusion, that is, they antagonize the potential pathogen by
the production of inhibitory compounds or by competition for nutrients and/or space
(Verschuere et al., 2000). It is also likely that probiotics stimulate a humoral and/or
cellular response in the host. The first report citing probiotics as a biological control in
aquaculture was in the late 1980‟s. In this mode of farming, probiotics are usually
introduced as part of the feeding regimen or applied directly to the water. A variety of
microorganisms, ranging from aerobic Gram-positive bacteria (Bacillus spp. (Raengipat
et al., 1998)), to Gram-negative bacteria (Vibro spp. (Irianto and Austin, 2002)) and yeast
(Scholz et al., 1999) have been utilized successfully to increase the commercial yield of
farmed marine animals. Several species of microalgae have also effectively been used for
this purpose. Of note, the unicellular alga, Tetraselmis suecica, has been used as feed for
penaeids and salmonids with significant reduction in the level of bacterial diseases. The
probiotic activity of T. suecica was first reported by Austin et al. (1992). These
investigators went on to show that when used as a food supplement, the algal cells
inhibited laboratory-induced infections in Atlantic salmon by Aeromonos hydrophila, A.
salmonicida, Serratia liquefaciens, Vibrio anguillaram, V. salmonicida and Yersenia
ruckeri type I (Austin et al., 1992). Although the precise mode of action of T. suecica is
unknown it is suspected that unspecified antimicrobial components in the algal cells
9

might have contributed to its probiotic activities. Along these lines, Avedano and
Riquelme (1999) reported the possibility of incorporating bacteria with the ability to
produce inhibitory substances into an axenic culture of Isochrysis galbana. Thus, this
microalga could serve as a vector for transmitting inhibitory substances into cultures of
larval bivalves to antagonize pathogenic bacteria.
USE OF VACCINES IN AQUACULTURE
In recent years, vaccines based on recombinant DNA technology appear to be a
promising approach to controlling infectious diseases in farmed fish and certain
shellfishes (Biering et al., 2005; Clark and Cassidy-Hanley, 2005; Heppel et al., 1998).
By intramuscular injection of eukaryotic expression vectors encoding the sequence of a
pathogen antigen, DNA vaccines offer a method of immunization that overcomes many
of the disadvantages such as risk of infection and high costs of traditional live attenuated,
killed or subunit protein-based counterparts. They induce strong and long-lasting humoral
and cell mediated immune responses in fish which have made them attractive for the
aquaculture industry (Heppel and Davis, 2000). DNA vaccination has already been
proven to be effective in rainbow trout for infectious haematopoietic necrosis virus
(Boudinot et al., 1998; Corbeil et al., 1999; Kim et al., 2000; Kurath et al., 2006;
Lorenzen et al., 2001; Lorenzen et al., 1999) and viral haemorrhagic septicemia virus
(Lorenzen et al., 2002) as well as channel catfish for ictalurid herpes virus 1 (Nusbaum et
al., 2002). After intramuscular injection of plasmid DNA carrying promoter-driven
reporter genes, protein expression has been achieved in tilapia (Rahman and Maclean,
1992), goldfish (Kanellos et al., 1999), zebrafish (Heppel et al., 1998), Japanese flounder
(Takano et al., 2004) and gilthead seabream (Verri et al., 2003).
10

Although there are several ways to administer vaccines, most young fish continue
to be vaccinated by hand. In Norway, for example, over 200 million fish are vaccinated
each year. Each fish is removed from the water, anesthetized and vaccinated. This
method is highly stressful for the fish, and in some circumstances rather impractical.
Another method of vaccination is by dip immersion into a solution containing the
vaccine. Dip immersion is usually used in fish stocks that are too young or small for
manual handling. Unfortunately, this method alone is not sufficient to achieve a long
duration of protection. Thus, the fish are usually subjected to intra-peritoneal revaccination injection as soon as their size allows. Oral vaccine delivery systems are by
far the most desirable method for immunizing fish. However, this system has proven
ineffective. A vaccine approach has not been explored in disease control in shrimp in
farm conditions because of the lack of adaptive immune system, although, recent
approaches to induce quasi-immune response using viral proteins and double stranded
DNA is somewhat successful in lab-based studies. However, vaccination of individual
shrimp is simply impractical in field condition because of the fragile body nature and
high physiological stress compared to fish when taken out of water. All these hurdles
point to the need for the development of a more user-friendly and field oriented
methodologies for infection control particularly in shrimp aquaculture (Lin et al., 2005).
PARATRANSGENESIS
Paratransgenesis is a relatively novel approach for the control of vector-borne
infectious disease transmission. Paratransgenesis is a „Trojan horse‟ approach to control
of disease transmission by insects. It employs the interactions between diseasetransmitting vectors, bacterial symbionts of the vectors, and the pathogenic agent (Beard
11

et al., 2002; Dotson et al., 2003; Durvasula et al., 1997; Durvasula et al., 1999).
Symbiotic bacteria are isolated and genetically transformed in vitro to export molecules
that interfere with pathogen transmission. The genetically altered symbionts are then
introduced into the host vector, where expression of engineered molecules affects the
host's ability to transmit the pathogen, i.e., its vector competence. This approach attempts
to decrease pathogen transmission without adverse effects on the vectors themselves.
Furthermore, it employs, as a gene delivery mechanism, bacterial flora native to the host
vector. There are several requirements for classical paratransgenic approach to be
successful and the most important ones are listed below:
1.

An appropriate symbiotic association must exist within a given diseasetransmitting vector.

2.

Bacterial symbionts should be amenable to culture and genetic
manipulation.

3.

Genetically altered symbionts should remain stable.

4.

Fitness of the genetically altered symbionts to re-infect host vectors
should not be compromised. Furthermore, their normal symbiotic
functions should not be altered.

5.

Transgene products released from the genetically altered symbionts
should interact effectively with the target pathogen.

6.

A method must exist for dispersal of the genetically altered symbionts
amongst naturally occurring populations of vectors.
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Durvasula et al. (1997) conducted the initial proof of concept studies on this approach
to combat transmission of the Chagas disease parasite, Trypanosoma cruzi, by reduviid
bug vectors (Fig. 1).

Figure 1. Paratransgenic disease control against Chagas disease. Complementary DNA
encoding cecropin A, an antiparasitic peptide, is cloned into a plasmid vector. After
transformation of Rhodococcus rhodnii with the vector, this bacterial symbiont that
normally lives in the intestine of the reduviid bug (Rhodnius prolixus), expresses
cecropin A, and the hindgut of these nymphs becomes colonized with transgenic R.
rhodnii. The colonized nymphs are then allowed to feed on human blood containing
living Trypanosoma cruzi, the agent of Chagas' disease. T. cruzi are reduced or
eliminated in insects colonized with the transformed R. rhodnii (Conte, 1997)
Many research groups have since applied this concept for the intervention of
numerous infectious diseases such as for the commensal bacteria of the human
respiratory tree (Sundaram et al., 2006), sharpshooter vectors of the grape bacterial
disease, Pierce‟s Disease (Bextine et al., 2004), sandfly vectors of leishmaniasis
(Hillesland et al., 2008), and mosquito vectors of malaria (Favia et al., 2007; Ren et al.,
2008).
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MARINE PARATRANSGENESIS
The classical paratransgenesis consisted of four elements; the arthropod insect
vector, the symbiotic bacteria which resides in the vector, the disease causing agent
and human, the host which succumbs to the disease. A closer look at the shrimp culture
system also reveals a similar biological system. In large-scale shrimp rearing, larval
stages are fed with Artemia -an aquatic crustacean feed organism- to boost nutrition
and improve survival in hatcheries. Artemia, which are reared separately, are fed with
microalgae and other probiotic bacteria. Artemia is a nearly ideal feed organism:
economical, hardy, and readily available worldwide. For the nutritional purpose of
Artemia, they are fed with microalgae and probiotic bacteria. So similar to the classical
paratransgenesis, there are four elements associated with shrimp culture system; the
Artemia which is the arthropod intermediate, the microalgae feed organisms, the
disease-causing bacteria such as Vibrio, Aeromonas etc, and finally the host, shrimp,
which succumbs to the disease.
The supplementation or bioencapsulation of nutritional components, such as
vitamins or calcium, into Artemia has been practiced by aquaculture hatcheries for
over 10 years. Artemia nauplii were initially fed with emulsified fish oils containing
highly unsaturated fatty acids (HUFA), to eventually be used as feed for marine finfish
and crustacean larvae. Today, live nauplii of the brine shrimp have been used as
vectors for delivering compounds of diverse nutritional (Dhert et al., 1999) and/or
therapeutic (Campbell et al., 1993) value to larval stages of aquatic animals.
Inoculating the digestive tracts of target organisms with probiotic bacteria through
bioencapsulation is another alternative use for Artemia nauplii. Bacteria with various
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characteristics have also been incorporated into Artemia nauplii prior to oral challenge
of turbot larvae with a pathogenic Vibrio anguillarum strain (Chair et al., 1994a;
Grisez et al., 1996). This route has also been used to vaccinate sea bass fry (Chair et al.
1994b); juvenile carp (Joosten et al., 1995) and fish fry (Campbell et al., 1993).
We propose a modified paratransgenic approach to control infectious diseases of
shrimp culture. Lines of marine cyanobacteria, algae and diatoms - common
components of feed for farmed shrimp and fish - can be transformed to produce
antibodies that neutralize infectious pathogens such as WSSV and Vibrio. Delivery of
these feed organisms, either directly in slurry preparations or via a bioamplification
strategy with Artemia, will result in passive immunization of the alimentary tract of
farmed marine animals. This is the portal of entry for many infectious agents and the
delivery of neutralizing antibodies would either abort the infectious process or delay it
sufficiently to permit harvest. We have demonstrated that a marine cyanobacterium,
Synechococcus bacillarus, could be genetically transformed to express a functional
recombinant antibody (Durvasula et al., 2006). We transformed S. bacillarus to
produce a murine antibody (rDB3) against progesterone, using a heterologous
expression system. In competitive ELISA studies, the rDB3 antibody bound
progesterone in a dose- dependent and specific manner. No cross-reactivity with
testosterone, a structurally similar steroid, was detected (Durvasula et al., 2006). This
study demonstrated that a transgenic cyanobacterium could elaborate an active
recombinant antibody, and serves as a model for future applications of this technology.
An alternate strategy for delivery of transgenic Dunaliella to the target animal is via
bioamplification. In this strategy a feed organism such as Artemia initially consumes
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the transgenic Dunaliella. The engorged Artemia is then fed to the target animal. In
this manner, the supplement is bioamplified as it progresses up the food-chain.
Artemia are non-selective filter feeders and therefore will ingest a wide range of
foods. The main criteria for food selection are particle size, digestibility, and nutrient
levels (Dobbeleir et al., 1980). Possibly the best foods for Artemia are live microalgae
such as Nannochloropsis, Tetraselmis, Isochrysis, Dunaliella and Pavlova.
Combinations of live phytoplankton fed to Artemia cultures have demonstrated
superior enrichment characteristics over feeding single phytoplankton species
(D‟Augostino, 1980). However, not all species of unicellular algae are appropriate for
sustaining Artemia growth. For example, Chlorella and Stichococcus have a thick cell
wall that cannot be digested by Artemia.
CONCLUSIONS
There are two dominant issues in shrimp aquaculture industry; 1) An increasing
trend of seafood demand from the planet‟s growing population whereas the seafood
supply is hugely affected by infectious diseases 2) The ban of large scale use of
antibiotics in aquaculture sector and ineffectiveness of other traditional methods to
ward off shrimp infections. Therefore, a major challenge in shrimp aquaculture is to
develop new methods of infectious disease control in shrimp aquaculture. The main
objective of this study is to conduct the proof of concept studies on developing marine
paratransgenic approach as a sustainable, cheap and practical method of infectious
disease control in marine shrimp farming. The aims and subaims of the study are listed
in the following page.
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MAJOR AIMS OF DISSERTATION RESEARCH

AIM 1: DEMONSTRATE THE CONCEPT OF PARATRANSGENESIS IN
AQUACULTURE
Sub aim 1.1. Development of paratransgenic Artemia: A potential strategy for control of
infectious diseases of commercial mariculture.

Sub aim 1.2. Develop the concept of biotransfer/bioamplification of recombinant
proteins in marine paratransgenic approach.

AIM 2: USE OF ANTIMICROBIAL PEPTIDES (AMPS), EITHER INDIVIDUALLY
OR IN COMBINATION AGAINST VIBRIO SPP.
Sub aim 2.1. Minimum inhibitory concentration (MIC)/ Minimum bactericidal
concentration (MBC) experiments with single AMPs against pathogenic Vibrio spp.
Determine whether AMPs in combination have synergistic actions and less probability of
emergence of resistance mechanisms against peptides.

Sub aim 2.2. Cloning of AMPs into expression vectors and transformation into Bacillus
subtilis strains. Characterization of the transgenic clone and AMP expression and antivibrio activity of these clones.

17

CHAPTER 2
DEVELOPMENT OF PARATRANSGENIC ARTEMIA
This chapter is based on the following published article:
Subhadra, B., Hurwitz, I., Fieck, A., Subba Rao, G., Subba Rao. D. V., Durvasula, R.,
2009. Development of Paratransgenic Artemia as a Platform for Control of Infectious
Diseases in Shrimp Mariculture. Journal of Applied Microbiology 106:831-840.
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SUMMARY
Aim: To study the accumulation and retention of recombinant proteins in Artemia gut for
optimizing paratransgenic disease control in shrimp aquaculture. Materials and Results:
Transgenic Escherichia coli expressing fluorescent marker proteins and the transgenic
cyanobacterium Synechococcus bacillarus expressing a functional murine single chain
antibody, DB3, were fed to Artemia franciscana. Stable expression and retention of
marker molecules up to 10 h after feeding with E. coli were evident within the gut of
Artemia. Engineered strains of S. bacillarus expressing DB3 accumulated within the gut
of Artemia, with detectable antibody activity for 8-10 h of feeding via ELISA, coincident
with the time period of highest density of transgenic S. bacillarus in the Artemia gut.
Conclusions: Artemia fed transgenic bacteria or algae accumulated recombinant proteins
for up to 10 h, which retained biological activity. Co-delivery of multiple recombinant
proteins simultaneously in the gut of Artemia was also demonstrated. Significance and
Impact of the study: Expression of molecules which target infections agents of
mariculture in shrimp via commonly deployed feed organisms such as Artemia could
potentially offer powerful new tools in the ongoing global effort to increase food supply.
INTRODUCTION
Production loss to due to infectious diseases causes huge losses to shrimp farmers.
Noval apporoaches against infectious disease control in shrimp is a pressing need. In this
paper, we explore the application of paratransgenic strategies to target infectious diseases
of shrimp aquaculture. To apply this strategy to farmed shrimp, we propose a modified
paradigm that involves microbes that are frequently used as feed for marine animals
(Durvasula et al., 2006). Probiotic bacteria such as Bacillus subtilis and marine
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cyanobacteria are commonly deployed feed organisms in commercial mariculture
settings. Though they are not true symbiotic organisms, they can serve as effective
delivery vehicles for foreign proteins that disrupt transmission of pathogens. The
continuous delivery of these feed organisms in commercial mariculture coupled with
rapid assimilation of feed products by animals such as shrimp render this an attractive
platform for paratransgenic interventions. Furthermore, bacteria can be delivered to
farmed marine animals through intermediate mechanisms such as Artemia. Live food
such as microalgae and Artemia nauplii are provided throughout development of shrimp
larval stages to improve survival in hatcheries. We hypothesize that Artemia can be used
as an effective delivery mechanism for recombinant proteins which impart immunity to
shrimp against a variety of infectious pathogens. This paratransgenic method of
delivering antibody-producing cyanobacteria via Artemia to shrimp larval stages utilizes
the natural feeding behaviors of both Artemia and farmed shrimp. In this study, we
conducted experiements to show the Artemia fed with recombinant proteins expressing
cyanobacteria or E.coli will effectively accumulate functional proteins in their gut.
MATERIALS AND METHODS
Generating transgenic lines of E. coli and S. bacillarus
E. coli Nissle was provided by Dr Ulrich Sonnenborn, Ardypharm (Ardeypharm
GmbH, Germany). Both E. coli DH5α and E. coli Nissle were transformed with pGFP
which expresses Green Fluorescent Protein (Clontech Laboratories Inc., Mountain View,
CA, USA) using a calcium chloride transformation protocol. The pGFP plasmid
expresses Green Fluorescent Protein (GFP), a 27kDa that exhibits bright green
fluorescence when exposed to blue light and first isolated from the jellyfish Aequorea
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victoria (Prendergast and Mann, 1978). The DSRed plasmid was constructed by cloning
the DSRed gene into the Xho1/Xba1 sites in pET 21 (Novagen-Merck KGaA, Darmstadt,
Germany) and used to transform E. coli DH5α. The transformed bacterium expresses a
red fluorescent protein (DsRed) and this protein was originally isolated from reef coral,
Discosoma sp. (Dietrich and Maiss, 2002). Construction of the shuttle vector
pRrMDWK6 was previously described (Durvasula et al., 1999). The pRrMDWK6 vector
has the gene for rDB3 protein, which is a murine single-chain V/V antibody against
progesterone (He et al., 1995). Wild type S. bacillarus (CCMP1333) were purchased
from the Provasoli-Guillard National Center for Culture of Marine Phytoplankton and
cultured in sterile seawater supplemented with f/2 concentrate (Sigma-Aldrich, St Louis,
MO, USA) trace metals, and vitamins (CCMP, Bigelow Laboratory for Ocean Sciences,
West Boothway Harbor, ME, USA). S. bacillarus transformation with pRrMDKW6 was
performed by adapting protocols for E. coli, and had been previously described
(Durvasula et al., 2006).
Western Blot to detect DB3 protein from transgenic S. bacillarus lysates
Overnight cultures of wild type or transgenic S. bacillarus grown in f/2 media
were centrifuged at 3000 g for 15 min. The cells were lysed in lysis buffer (100 mM TrisCl, 500 mM NaCl, 0.5 M EDTA, 0.1% Triton X-100, 0.1% Tween-20, 8% glycerol, 250
mM urea, 5 mM β-2 mercaptoethanol, 100 µg ml -1 PMSF, 1 µg ml -1 protease inhibitor
cocktail, 50 µg ml -1 lysozyme) and proteins were concentrated using 80% saturated
ammonium sulfate precipitation followed by overnight dialysis against 25 mM Tris-HCl
(pH 7.2). One hundred µg of total protein, as determined by Bradford assay, was
electrophoresed on a 10% SDS-PAGE gel and transferred to PVDF membrane (BioRad,
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Hercules, CA, USA). The blot was blocked with 5% BSA in TBST (Tris buffered saline
containing 1% Tween 20) for 1 hour, and washed three times with TBST. The blot was
then probed with alkaline phosphatase-linked goat anti-mouse kappa chain antibody
(Southern Biotech, Birmingham, AL, USA) at a dilution of 1:5000 and developed using
an alkaline phosphatase immunoblot detection kit. This reaction involves hydrolyzation
of the primary substrate bromochloroindolylphosphate- ptoluidine by alkaline
phosphatase to form an intermediate that undergoes dimerization to produce an indigo
dye. The nitro-blue tetrazolium (NBT) is reduced to NBT-formazan (insoluble blackpurple precipitate) by the two reducing equivalents generated by the dimerization
(Chemicon Inc, Billerica, MA, USA).
Axenic hatching of Artemia
All experiments were performed with high quality hatching cysts of Artemia
franciscana (INVE Aquaculture, Baasrode, Belgium). Sterile cysts were obtained via a
de-capsulation protocol as adapted from the method of Marques et al. (2004). Cysts were
hatched in a conical flask containing 1000 ml sterile filtered artificial seawater. To assure
that nauplii were axenic, random Artemia were selected and homogenates were incubated
on LB-seawater agar for 72 h at 37 °C.
Fluorescence microscopy to detect GFP and DS Red protein in the gut of
paratransgenic Artemia
106 CFU ml -1 of wild type or transgenic E. coli expressing fluorescent proteins
(GFP or DSRed) were fed to Artemia (200 Artemia ml -1). At intervals of 30 min, 2, 4, 6,
8 and 10h, 3-4 Artemia nauplii were anesthetized by immersion into a 30 mg l -1 of
tricaine methanesulfonate (Sigma-Aldrich, St. Louis, MO, USA) solution, and suspended
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in a single drop of sterile PBS on a microscopic slide. Fluorescent microscopic images
(10X objective magnification) were taken using a Zeiss Axioshop LSM 510 fluorescent
microscope (Carl Zeiss Meditech Inc. Dublin, Ireland). All images were exported as tiff
files and compiled in Slidebook software (Intelligent Imaging Innovations Inc., Denver,
CO, USA).
Culture and algal feeding of Artemia
Fortyeight hours after hatching, 20000 Artemia nauplii were transferred to sterile
250-ml Erlenmeyer flasks containing 100 ml of filtered and autoclaved artificial
seawater. Wild-type or transgenic S. bacillarus in f/2 media were washed in filtered
seawater and added to the feeding vessels to a final density of 106 CFU ml -1. Artemia
were harvested at 2, 4, 6, 8, 10 and 20 h for further analysis.
Preparation of gut content from Artemia and quantification of kanamycin- resistant
S. bacillarus
Gut contents of individual Artemia (n=100) were dissected out, disrupted using
sterile needles, suspended in 0.1 ml of sterilized seawater and cultured on LB-seawater
agar containing 50 µg ml -1 of kanamycin. The total number of kanamycin-resistant
colonies was counted and used to calculate the number of transgenic S. bacillarus
accumulated in each Artemia. Representative colonies were screened by PCR for the
DB3 gene.
PCR amplification for the detection of DB3 gene from Artemia gut extracts
The harvested Artemia were washed thoroughly 10-12 times with sterile seawater and
viewed under a light microscope to assure that clumps of cyanobacteria were not adhering to
the surface. The Artemia were gently homogenized in PBS buffer and 2 µl of extract was
23

used as template for PCR amplification of the 850bp gene as a doublet encoding DB3 using
the oligonucleotide primer sets DB3F 5‟-GCACCGCGGGAGC CCAGGTGAAACTGCTG3‟ (forward) and DB3R 5‟-CCTCGATTGCGGCCGCTTAAC-3‟ (reverse) (Durvasula et al.,
1999). Thermal cycling reactions consisted of an initial denaturation at 94°C for 2 min
followed by 32 cycles of denaturation at 94°C for 30s), annealing at 58°C for 30s, and
extension at 72°C for 60s), with a single final extension at 74°C for 2 min.
Western blot to detect DB3 protein from Artemia gut extracts
Dissected guts from Artemia were resuspended in 1 ml lysis buffer and placed on
ice for 20 min before 3 rounds of sonication (50-60 s duty cycles, 5-6 output). The lysate
was centrifuged at 19000 g for 25 min, 4°C and the supernatant precipitated with
saturated ammonium sulfate (Sigma-Aldrich, St. Louis, MO, USA). Protein was
recovered by centrifugation at 19000 g for 25 min at 4°C. The protein pellet was dialyzed
into 250 mM Tris-HCl (pH 7.2) with a 7 kDa Slide-A-lyzer (Pierce Biotechnology Inc.,
Rockford, IL, USA) overnight at 4°C. The dialyzed protein was then concentrated using
Nanosep 30K spin columns (Pall Corporation, Ann Arbor, MI, USA). Equal amounts of
protein as determined by Bradford assays were separated on 4-16% gradient SDS-PAGE
gel (Bio-Rad, Hercules, CA, USA), and transferred to PVDF membrane (Bio-Rad,
Hercules, CA, USA). Western blot analyses were performed as described above.
ELISA to detect DB3 protein progesterone binding activity from Artemia gut
extracts
High-binding capacity 96-well polystyrene plates (Poly-Sorb, NuncTM) were
coated with 6 µg Progesterone-CMO-BSA conjugate (Fitzgerald Inc., Concord, MA,
USA) per well in a carbonate capture buffer (pH 9.5) at 37oC overnight. After three
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washes in TBST, the wells were blocked with 2.5% BSA (Fisher Scientific, Pittsburgh,
PA, USA) for 1 h at 37°C. Positive control anti-progesterone IgG (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) or sample lysates were added in 100 µl TBST to triplicate wells and incubated at 37oC for 2 h. The wells were washed as before and
100 µl of a 1:3000 dilution of goat-anti-mouse kappa chain IgG conjugated to
Horshradishperoxidase was added (Southern Biotech, Birmingham, AL, USA) followed
by incubation at 37oC for 1 h. After a final set of three washes, 100 µl of
tetramethylbenzidine peroxidase substrate (Bio-Rad, Hercules, CA, USA) was added to
each well and color development to blue was allowed for 2 minutes. Color development
was stopped with 100 µl 1mol l -1 H2SO4 per well and the plates were analyzed on an
ELISA plate reader (Molecular Devices, SupectraMAX 250, Sunnyvale, CA, USA) at
450nm.
Recombinant GFP protein dynamics in Artemia gut
The dynamics of a marker molecule within the gut of Artemia was determined in
the following wash-out experiment. Artemia, at density of 20 Artemia ml-1, were fed for
5 h with 106 CFUml-1 E. coli expressing GFP. Fifty Artemia were removed from the tank
at 0.5, 1, 3, and 5 h for gut extract preparation as described above. The remaining
Artemia in the tank was washed with sterile saline and transferred to a tank with no feed
organism for another 5 h. Fifty Artemia were removed at 0.5, 1, 3, and 5h for sampling.
In the control experiment, Artemia were fed continuously for 10 h with 106 CFUml-1 E.
coli Nissle expressing EGFP. During this period, samples of 50 Artemia were removed at
0.5, 1, 3, 5, 8 and 10 h for gut extract preparation as described above. The experiments
described were performed in triplicate. GFP was quantified as described below.
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ELISA for quantifying rGFP
The rGFP was quantified using a commercial kit (GFP ELISA kit, Catalog #AKR
121, Cell Biolabs Inc, San Diego, USA) with few modifications in the kit protocol. The
assay was optimized for the experiment using recombinant GFP spiked in Artemia extract
to obtain a standard curve within the linear range of 1-25 ng of rGFP. Briefly, one
hundred microlitre aliquots of serially diluted Artemia extracts were bound to the wells of
antibody coated assay plates at 37°C for 3 h. After washing three times in wash buffer,
the wells were blocked with 2.5% BSA in TBST for 1 h at 37°C. One hundred microlitres
of a 1: 3000 dilution of primary anti-GFP antibody was added followed by incubation
overnight at 4°C. Following incubation, the wells were washed as before and 100 µl of a
1: 5000 dilution of secondary antibody conjugated to horseradishperoxidase was added.
Plates were allowed to incubate at 37°C for 1 h, and after a final set of three washes, 100
µl of tetramethylbenzidine peroxidase substrate solution was added to each well. Colour
development was stopped after about 10 min with stop solution. Absorbance at 450 nm
was determined on a SupectraMAX 250 Plate Reader.
Quantification of GFP+ E. coli Nissle in Artemia gut extracts
Serially diluted Artemia homogenates were plated in triplicate onto LBcarbenicillin+ plates and grown overnight at 37oC. Colony counts were determined from
each plate. Representative colonies of the last three LB- carbenicillin + dilution plates
showing growth were isolated and was subjected to colony PCR to confirm E. coli Nissle
strain using specific primers pMUT2-F (5′-GAC CAA GCG ATA ACC GGA TG-3′) and
pMUT2-R (5′-GTG AGA TGA TGG CCA CGA TT-3′) (Blum-Oehler et al., 2003).
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Presence of GFP expression from these representative colonies were confirmed by
viewing under fluorescent microscope.
Statistical Analyses
The GFP concentrate and transgenic CFU count from the protein dynamics study
were subjected to Students t test, and a p≤ 0.05 was considered significant. A statistical
software GraphPad Prism was used (GraphPad Software, Inc., San Diego, CA) to
perform this analysis.
RESULTS
GFP and DS Red protein in the gut of paratransgenic Artemia
Fig.2b shows by fluorescence microscopy that GFP-expressing E. coli
accumulated in the gut of Artemia following 30 min of feeding; no fluorescence was
observed in control Artemia that were fed on wild-type E. coli for up to 6 h (Fig. 2a).
Fluorescence increased following 4 h and 10 h of feeding suggesting an accumulation of
green fluorescent protein over time (Fig. 2b, c, d). Our data would suggest that
recombinant proteins can accumulate in Artemia gut and retain biological activity. We
then tested whether multiple protein products, expressed simultaneously by different
bacterial populations, could accumulate in the gut of the Artemia via this method. For
this, we fed Artemia with two strains of transgenic E. coli expressing GFP and DS Red.
Fluorescent images taken at 6 h of feeding show that both GFP and DS Red accumulated
in the Artemia gut (Fig. 2f).
DB3 protein from transgenic S. bacillarus lysates
S. bacillarus transformed with DB3 gene was used for our subsequent studies on
retention and bioactivity of recombinant protein products in the gut of Artemia. Western
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analysis revealed a 42 kDa protein of murine origin that was expressed by transformed S.
bacillarus; wild-type S. bacillarus did not elaborate this protein (Fig. 3).

Figure 2. Fluorescent microscopy shows increased accumulation of recombinant proteins
in a time dependent manner in 2nd instar nauplii of Artemia fed with fluorescent-protein
expresssing E. coli. a) Artemia fed with wild type E. coli after 6 h of feeding b) Artemia
fed with GFP-expressing bacteria after 30 min of feeding c) 4 h of feeding d) 10 h of
feeding e) Artemia fed with DS Red expressing bacteria after 6 h of feeding f) Artemia
fed simultaneously with both GFP- expressing bacteria and DS Red-expressing E. coli
after 6 h of feeding.

Quantification of kanamycin-resistant S. bacillarus
The gut of second instar Artemia nauplii contained 4.2 x 104 CFU of recombinant
S. bacillarus after 2 h of feeding. The number of CFU peaked to 1.5 x 105 at 8 h of
feeding, followed by a slow decrease to 4.9 x 103 CFU after 20 hours of feeding (Fig. 4).

Figure 3. rDB3 expression in S. bacillarus transformed with
pRrMDKW6. Lane 1, lysate from Transgenic S. bacillarus cells for
DB3 expression; Lane 2, lysate from wild type S. bacillarus cells;
Lane 3, recDB3 protein (purified from E. coli as positive control);
Lane 4, Trichrom ranger TM Molecular marker.
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Figure 4. Total colony forming units (CFU) of transgenic S. bacillarus (kanamycin resistant
colonies) from Artemia gut extracts fed with transgenic S. bacillarus at progressive time
intervals. Values are means  S.E. of three feeding tanks per treatment.

DB3 gene from Artemia gut extracts
PCR amplification was used to detect the 850 bp rDB3 murine V/V gene from
Artemia fed with transgenic S. bacillarus. Fig. 5 shows the presence of the DB3 gene
from gut extracts of Artemia fed with transgenic S. bacillarus. The 850 bp product was
absent from gut extracts of Artemia fed with wild type S. bacillarus.

Figure 5. PCR amplification for the detection of DB3 gene from Artemia gut extracts.
Lane 1, 1 Kb DNA ladder. Lane 2, positive control (pRrMDWK6). Lane 3, 5, 7, 9 and 11
represents PCR products from Artemia gut extracts fed with wild type S. bacillarus after
2, 4, 8, 10 and 20 h after feeding. Lane 4, 6, 8, 10 and 12 represents PCR products from
Artemia gut extracts fed with transgenic S. bacillarus after 2, 4, 8, 10 and 20 h after
feeding.
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Detection of DB3 protein in gut of paratransgenic Artemia
Gut extracts were prepared from harvested Artemia samples to detect expression of the
rDB3 antibody. Western blot analysis using a goat anti-mouse kappa antibody detected a
band of 42 kDa in gut extracts of Artemia fed recombinant cyanobacteria following 2 h
of feeding (Fig. 6). The size and murine origin of the protein in the paratransgenic
Artemia confirms that it is recombinant DB3 antibody. Protein densitometric analysis of
the blot also showed a progressive increase in amount of rDB3 antibody from 2 h to 8 h
of feeding and a small decrease thereafter (not shown). Gut extracts of Artemia fed with
wild type S. bacillarus did not display any signal with the anti-mouse antibody.

Figure 6. Western blots to detect DB3 protein from Artemia gut extracts. Lane 1,
Trichrom ranger TM Molecular marker. Lane 2, 4, 6, 8, and 10, Artemia fed wild type S.
bacillarus and harvested 2, 4, 8, 10 and 20 h after the commencement of feeding. Lane 3,
5, 7, 9 and 11, Artemia fed transgenic S. bacillarus and harvested 2, 4, 8, 10 and 20 h
after the commencement of feeding.

DB3 protein progesterone binding activity from the gut of paratransgenic Artemia
Artemia gut extracts were used for ELISA on plates coated with progesterone 3(O carboxymethyl) oxime-BSA conjugate. Gut extracts of paratransgenic Artemia
demonstrated binding to progesterone-BSA, with values increasing from 0.12 to 0.29
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O.D. between 2 and 10 hours of feeding (Fig. 7). Gut extracts of Artemia that were fed
wild type S. bacillarus yielded a background of ~0.07 O.D. which was not significantly
different from extracts isolated from unfed Artemia (data not shown). Extracts from
paratransgenic Artemia showed a twofold increase in progesterone binding activity from
2 h to 6 h of feeding and the binding activity continued to increase to at least 10 h of
feeding. This suggests that breakdown of cyanobacteria in the gut of paratransgenic
Artemia continued for several hours, with accumulation of functional rDB3 antibody for
10 h of feeding.

Figure 7. ELISA demonstrating progesterone-binding activity of gut extracts of Artemia
fed with DB3-producing S. bacillarus or wildtype S. bacillarus. Values are means  S.E.
of three feeding tanks per treatment.

GFP protein dynamics in the Artemia gut
To study dynamics of a recombinant protein in Artemia gut we quantified the
accumulation of rGFP via ELISA. In Artemia that were fed continuously for 10 h, gut
concentration of the recombinant protein reached a peak value of 12.4 ± 0.3 ng rGFP g-1
after 8 hours. At 10 hours, a slight decrease was noted to 10.4 ± 0.3 ng rGFP g-1 (Fig.
8A). The transgenic bacteria accumulation in Artemia gut also peaked at 5 h in continous
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feeding and thereafter the level remained more or less same (Fig. 8B). In the
complementary trial in which Artemia were fed continuously for 5 h followed by a 5 h
wash-out period, gut concentration of the recombinant protein reached a peak value of
9.2 ± 0.7 ng rGFP g-1 at 5h. After 30 minutes of transfer to the wash-out phase,
recombinant protein concentration significantly decreased to 7.3 ± 0.6 ng rGFP g-1
followed by a sharp decrease to 3.7 ± 0.4 ng rGFP g-1 and 2.6 ± 0.4 ng rGFP g-1 at 8h and
10 h, respectively. (Fig. 8A). The transgenic bacteria accumulation in Artemia gut
showed a sharp decline during the 5 h
wash-out period (Fig. 8B).
Figure 8. A) Recombinant GFP
accumulation in Artemia gut. Animals
were either fed continuously for 10 h
or fed for 5 h followed by a 5 h
washout period during which no feed
organisms were given. B) Total colony
forming units (CFU) of transgenic E.
coli +carbenicillin+ from Artemia gut
fed continuously for 10 h or fed for 5
h followed by 5 h washout. Values are
means  S.E. of three feeding tanks per
treatment.

DISCUSSION
Here we report a modified paratransgenic approach with the brine shrimp,
Artemia franciscana. Using genetically transformed variants of E. coli Nissle and S.
bacillarus, two feed organisms of shrimp, we have demonstrated delivery, retention and
biological activity of recombinant proteins in the gut of Artemia. In this study, a non32

pathogenic E. coli is used as a platform for expression of fluorescent marker proteins in
the gut of Artemia. Stable expression of these fluorescent markers, GFP and DS Red,
throughout 10 hours of continuous feeding suggests that recombinant proteins can be
delivered effectively to nauplii of Artemia and retain their biological activity.
Furthermore, co-expression of multiple markers simultaneously in the gut of Artemia
confirms that paratransgenic manipulation of these animals for delivery of a battery of
molecules with activity against pathogens is possible. This strategy will be quite
significant in settings of drug-resistant pathogens where concurrent delivery of molecules
that act at different target sites of the pathogen would slow the emergence of resistant
species.
Though the role of Artemia as a food source for larger commercially important
animals such as shrimp has been evaluated (Chair et al., 1996; Dhont and Sorgeloos,
2002), no studies have considered engorging Artemia with recombinant proteinexpressing bacteria or algae for delivery to shrimp. Our studies showed that Artemia
nauplii fed to engorgement with antibody-producing cyanobacteria retained functional
recombinant protein. Western blot analysis confirmed that the murine antibody, rDB3,
was present in gut extracts of Artemia that engorged on genetically altered cyanobacteria
after just two hours of feeding. The expected band at 42 kDa that was recognized by a
goat anti-mouse kappa chain IgG represents the recombinant DB3 molecule. Additional
bands seen at 70 kDa and above in the gut extracts of paratransgenic Artemia only could
represent multimeric covalent assemblies of VH and kappa regions that were recognized
by the anti-mouse kappa chain antibody (He et al., 1995; Durvasula et al., 1999). No
proteins in the gut extracts of Artemia that were fed with wild-type cyanobacteria were
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recognized by the anti-mouse kappa chain antibody, indicating that expression in
paratransgenic Artemia was attributable to the engineered cyanobacteria.
Recombinant S. bacillarus reach a maximum of approximately 105 CFU in the gut
of Artemia at 8 h of feeding suggesting that maximum engorgement occurs at this point.
Several factors may account for the decrease in recombinant S. bacillarus CFU after this
time point. A reduction in the bacterial load may be due to the degradative properties of
Artemia gut. The absence of kanamycin selection in the Artemia tank raises the
possibility of plasmid decay. Populations of recombinant S. bacillarus, carrying the
pRrMDWK6 plasmid, could have reverted to the wild-type genotype resulting in steady
decrease in CFU of recombinant cyanobacteria. However, replica plating of samples of
Artemia gut taken beyond the 8 hour time point, did not reveal a significant shift from the
transformed to wild-type cyanobacteria. Alternatively, depletion of the transgenic
cyanobacteria from the Artemia tank could have occurred after 8 hours, though colony
counts of cyanobacteria in the tank water remained stable, suggesting ongoing
replication. Colony counts at 8 hours of feeding most likely represented the homeostatic
threshold of these bacteria in Artemia gut. Despite the slight decrease in cyanobacterial
CFU after 8 hours, maximum progesterone-binding activity from Artemia gut was noted
at 10 hours of feeding, suggesting accumulation of the recombinant antibody.
The dynamics of recombinant protein expression and accumulation in the gut of
Artemia were studied using a probiotic strain of E. coli Nissle (Grozdanov et al., 2004)
transformed to express GFP. In this experiment we addressed the question of whether
transformed feed bacteria and their recombinant protein products would be retained in the
gut of Artemia in the absence of a continuous supply of feed organisms. Whereas
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Artemia subjected to a 10 hour continuous feed with GFP-producing E. coli demonstrated
accumulation of both bacteria and protein to a threshold value, animals that were
transferred from a feed source to a new environment without transgenic feed bacteria
exhibited very rapid loss of both GFP-producing bacteria and the protein product within 5
hours. Indeed, these results suggest that the Artemia gut is a conduit through which
recombinant feed organism‟s transit. The majority of foreign protein production in this
type of modified paratransgenic system is therefore related to molecules that are
continuously synthesized by feed organisms that have been transformed with constitutive
promoter elements. A small number of transgenic E. coli and their recombinant GFP
products remained in the gut of Artemia 5 hours after the animals were transferred to an
environment with no added feed. However, the relative role of feed bacteria that actually
establish in the gut of these animals and produce molecules in situ appears to be minimal.
Under commercial settings such as shrimp hatcheries, Artemia can readily be fed to
engorgement with bacteria or algae, with subsequent delivery to tanks of shrimp within 6
to 8 hours. The rapid accumulation of foreign proteins over this time period indicates that
this approach could have utility in mariculture operations.
Taken together, the data showing co-delivery of multiple populations of
recombinant bacteria and establishment of paratransgenic Artemia capable of
accumulating functional antibodies illustrate that a paratransgenic model can be
developed to express foreign proteins in the gut of Artemia, through commonly deployed
feed algae and bacteria. Our feeding trials were conducted under sterile and controlled
culture conditions, which do not reflect hatchery settings for rearing Artemia. The
competition from environmental and microbial flora of the Artemia itself could greatly
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impact abundance of recombinant bacteria in the gut of paratransgenic brine shrimp, thus
decreasing the accumulation of recombinant proteins. Effects of such competition should
be studied further in controlled laboratory trials. In commercial hatcheries, feeding of
Artemia to shrimp larval stages occurs when there is sufficient yolk sac associated with
egg cysts to render superior nutritional quality to the shrimp. We used 2nd instar nauplii
for our feeding trial with completely depleted yolk sac nutrients, which were thus forced
to graze on cyanobacteria. The potential effects of these more mature paratransgenic
Artemia on nutrition and growth of target shrimp larval stages should also be studied.
Expression of the rDB3 antibody that binds progesterone, serves as a proof-ofconcept and has no immediate application toward infectious pathogens of mariculture.
However, it is an important precursor to ongoing studies directed at expression of
molecules with potent anti-viral and anti-Vibrio activity. Substitution of the DB3 gene
with genes encoding anti-bacterial and anti-viral proteins, with subsequent delivery of
paratransgenic Artemia to shrimp could offer new methods of defense against infections.
The cecropins, penaeidin, mellitin and moricin are cationic antimicrobial peptides which
exhibit very high lytic activity against gram negative bacteria (Destoumieux et al., 2000;
Zasloff, 2002; Chiou et al., 2005). These molecules may eventually be expressed in
shrimp probiotic bacteria (e.g. Bacillus subtilis) and algal feed organisms (e.g. S.
bacillarus and Dunaliella salina) to control vibriosis in intensive shrimp aquaculture.
Similarly, shrimp viral diseases might potentially be controlled via the modified
paratransgenic approach. Identification and cloning of antiviral peptides such as PmAV
(Penaeus monodon antiviral) have been reported from white spot virus-resistant P.
monodon (Luo et al., 2007). A high affinity monoclonal antibody (MAb 216) was
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developed against VP28, the anchor protein of white spot virus that facilitates viral entry
to the cytoplasm (Yi et al., 2004). Studies showed 80% survival benefits in white spot
virus-infected shrimp that were pre-treated with MAb 216 (Dante et al., 2007).
Engineered lines of S. bacillarus, D. salina and B. subtilis expressing PmAV and antiVP28 antibodies that are delivered to Artemia and, possibly, directly to P. monodon
might be a viable strategy to protect commercial shrimp against White Spot Syndrome
Virus infection.
Recombinant protein molecules and transgenic organisms might pose
environmental risks. Our laboratory had been engaged in risk assessment studies of
paratransgenic technologies for years. We have undertaken a comprehensive program to
evaluate toxicities of recombinant bacteria and potential for horizontal gene transfer.
These studies are requisites for approval by regulatory agencies and will facilitate
eventual application of paratransgenic technologies (Durvasula et al., 2007).
Technology aimed at development of paratransgenic shrimp which are refractory
to infectious pathogens under commercial hatchery and grow-out conditions is still at a
very early stage of development. Nevertheless, the ease with which common feed
organisms of farmed marine animals can be genetically engineered and delivered, either
directly or via an Artemia intermediate, suggests that this approach could eventually be
deployed in the commercial setting. Thus, the paratransgenic approach offers potential to
reduce the global burden of infectious diseases in commercial mariculture and improve
global food supply.
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CHAPTER 3
DEVELOPMENT OF A PARATRANSGENIC SHRIMP (LITOPENAEUS
VANNAMEI)
This chapter is based on the following article:
Subhadra, B., 2011. Development of a Paratransgenic Shrimp (Litopenaus vannamei).
Letter in Applied Microbiology (under preparation)
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SUMMARY
Novel paratransgenic approaches are being developed by our laboratory to control
the crippling effects of infectious diseases on mariculture. In this method, Artemia
engorged with recombinant protein expressing bacteria are fed to shrimp to accumulate
biologically active anti-infectious molecules. As a continued effort to further develop this
approach, we report results with recombinant protein marker molecules as a proof-ofconcept, aimed at development of paratransgenic white shrimp, Litopenaeus vannamei,
and a practical method of delivery of recombinant proteins to post-larval (PL) stages of L.
vannamei. Three feeding protocols aimed at delivery of recombinant proteins to L.
vannamei PL stages were conducted. Trial 1, which was designed to evaluate the
accumulation of an engineered antibody in the gut of L. vannamei, consisted of an 18 day
active feeding phase followed by 12 d wash-out phase. L. vannamei gut extracts showed a
progressive increase in signal of the recombinant antibody, DB3, from day 2 of feeding to
day 21. Rapid decrement in signal was noted on day 22; this reached undetectable levels
on day 30. In trial 2 and 3, which were designed to determine the dynamics of
recombinant GFP within the gut of paratransgenic L. vannamei fed with GFP expressing
bacteria engorged Artemia or fed directly with GFP-expressing EcN bacteria,
accumulation of GFP in shrimp was tightly coupled to periods of active feeding with
rapid depletion of recombinant molecules during a non-feeding wash-out phase. We
found no significant difference in the GFP levels in the shrimp fed with 20 or 40 Artemia
per shrimp per day. However, during initial feeding hours, a higher level of recombinant
GFP was seen in shrimp gut fed with Artemia engorged with transgenic bacteria
expressing GFP when compared to shrimp fed with transgenic bacteria. Here, we report,
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a practical paratransgenic delivery of bioactive recombinant molecules to the commercial
white shrimp, L. vannamei. Delivery of neutralizing-antibodies, cationic peptides, and
antivirals to shrimp by this approach has a great potential to control diseases in shrimp
mariculture.
INTRODUCTION
Recenly proposed marine paratransgenic approach to control shrimp diseases
involves delivering anti-infectious molecules such as antibodies and antivirals to shrimp
via Artemia and feed organisms such as algae and probiotic bacteria (Durvasula et al.,
2006), Our initial studies demonstrated that Artemia carrying engineered lines of bacteria
and algae accumulated recombinant proteins, which retained their biological activity for
up to 10 h (Subhadra et al., 2010). As a continued effort to deliver recombinant proteins
to shrimp for functional purposes, in the present study, we report results of three shrimp
feeding trials aimed at (1) develoment of paratransgenic white shrimp, Litopenaeus
vannamei, with marker molecules as a proof-of-concept (2) determining a practical
method of delivery of recombinant proteins to post-larval (PL) stages of L. vannamei.
Using the single chain antibody (DB3) (Subhadra et al., 2010), we demonstrate that the
paratransgenic strategy can be used to accumulate biologically active molecules such as
recombinant antibodies in the gut of L. vannamei. Furthermore, we show that
recombinant Green Fluorescent Protein (GFP) can be delivered effectively to the gut of L.
vannamei via direct feeding with engineered probiotic Escherichia coli Nissle (EcN)
strain or via engorgement with paratransgenic Artemia that carry the recombinant
bacteria. Ultimately, delivery of molecules with activity against infectious pathogens to
farmed shrimp could offer new approaches to control of lethal outbreaks in this industry.
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MATERIALS AND METHODS
Bacterial cultures, Artemia and Shrimp
Escherichia coli Nissle 1917 (EcN) is a nonpathogenic E. coli strain that has been
characterized extensively at the phenotypic and molecular genetic level (Blum-Oehler et
al., 2003; Grozdanov et al., 2004). EcN has evolved into one of the best characterized
probiotics with its therapeutic efficacy and safety has convincingly been proven (Kruis,
2005; Henker et al., 2007). EcN also has remarkable colonization characteristics in the
gut of diverse organisms (Westendorf et al., 2005). EcN was provided by Ardypharm
(Ardeypharm GmbH, Germany). EcN expressing GFP and the progesterone binding
single chain antibody, DB3, were generated as described in Chapter 2. All experiments
were performed with premium grade eggs of Artemia franciscana (BrineShrimp Direct,
Ogden, UT). L. vannamei PL (stages 10-12) were obtained from commercial shrimp seed
hatcheries (Harlington Shrimp Farm, Las Fresco, TX or Earthcare Aquaculture Inc.,
Weston, FL).
Feeding trial designs
Three shrimp feeding protocols were performed. The shrimp were acclimated for
5 days before the feeding trials to ensure adequate health. Two hundred shrimp averaging
4.5±0.03g in mass were selected and stocked in each of three 20-l tanks. Artemia were
hatched axenically and at the second naupliar stage were engorged with wild-type or
transgenic EcN expressing DB3 in engorging flasks at densities of 106 CFU ml-1. Trial 1
was a 30 d feeding trial designed to evaluate the tunable accumulation of an engineered
antibody in the gut of L. vannamei. It consisted of two phases. In phase 1, shrimp were
fed twice daily with paratransgenic Artemia that carried DB3-expressing EcN for 18 d.
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Shrimp were fed with 20 Artemia per shrimp per day (total of 4,000 Artemia per tank per
day). Phase 2 was a wash-out phase in which Artemia that carried wild-type EcN were
fed to shrimp for days 19 to 30. On days 1-5, a total of 12-15 shrimp PL‟s were sampled;
subsequently, 5-6 PL‟s were sampled on days 9, 12, 15, 19, 22, 25, 27, and 30. Dissected
gut contents from Artemia and shrimp were suspended in 1 ml lysis buffer (100 mM
Tris–Cl, 500 mM NaCl, 0.5 M EDTA, 0.1% TritonX-100, 0.1% Tween-20, 8% glycerol,
250 mM urea, 5 mM beta-2 mercaptoethanol, 100 µg ml -1 PMSF, 1 µg ml-1 protease
inhibitor cocktail, 50 µg ml-1 lysozyme) and placed on ice for 20 min before three rounds
of sonication. The lysate was centrifuged at 19 000 g for 25 min at4ºC, and the
supernatant precipitated with 80% saturated ammonium sulfate (Sigma-Aldrich). Protein
was recovered by centrifugation at 19 000 g for 25 min at 4ºC. The protein pellet was
dialyzed into 250 mM Tris–HCl (pH 7.2) with a 7 kDa Slide-A-lyzer (Pierce
Biotechnology Inc., Rockford, IL, USA) overnight at 4ºC. The samples were flash frozen
in liquid nitrogen and stored at -80 ºC for later use in ELISA. ELISA to detect DB3 and
GFP quantification in gut extracts were conducted as described in Chapter 2.
Trial 2 was performed to determine the dynamics of recombinant GFP within the
gut of paratransgenic L. vannamei. Shrimp were fed (20 or 40 Artemia/PL/d) engorged
with GFP-expressing EcN for 7 days followed by a 5 day wash-out phase during which
Artemia carrying wild-type EcN were used as feed. Shrimp PL‟s (n=4) were sampled on
days 1, 3, 5, 6, 7, 8 and 12 and shrimp gut extracts were prepared.
Trial 3 was designed to determine the dynamics of a recombinant GFP within the
gut of paratransgenic shrimp that were fed directly with GFP-expressing EcN at various
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concentrations (104, 105, and 106 colony-forming units ml-1) for 7 days followed by a 5
day wash-out phase during which wild-type EcN were used as feed.
Bacteriological assays
Shrimp samples were dissected using sterilized scissors to remove mid- and hindgut and weighed. To avoid possible external contamination while removing organs, the
surface of the shrimp was cleaned using 70% ethanol and allowed to dry. Shrimp gut
tissues were suspended in 1 ml PBS and the tissue was disrupted using sterile needles
before final re-suspension in 10 ml of sterile PBS. Bacteriological determination involved
serial dilutions of this suspension in PBS followed by plating in triplicate on LB and LB
supplemented with 50 µg ml-1 of kanamycin and carbenicillin to determine total
cultivable heterotrophic bacteria and transgenic E. coli, respectively. After overnight
incubation, colonies were counted and results were presented as CFU per shrimp.
Representative colonies were subjected to colony PCR using specific primers for both
DB3 forward primer:
5‟-GCACCGCGGGAGC CCAGGTGAAACTGCTG-3‟ and reverse primer: 5‟CCTCGATTGCGGCCGCTTAAC-3‟) and EcN forward primer: 5‟-GAC CAA GCG
ATA ACC GGA TG-3‟ and reverse primer: 5‟-GTG AGA
TGA TGG CCA CGA TT-3‟). For qualitative bacterial estimation, thirty to thirty-five
random colonies were picked from bacterial plates and were gram stained. These clones
were also subjected to PCR for GFP gene-specific primer set (GFP-Forward
5‟TCTGTCAGTGGAGAGGGTGA-3‟; GFP-Reverse,
5‟TCCATGCCATGTGTAATCCC 3‟) and EcN-specific primers sets.
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Statistical analyses
To determine statistically significant differences in concentration of GFP in
shrimp fed 20 or 40 Artemia per shrimp per day, we used the Students „t‟ test.
Statistically significant differences in GFP concentration in shrimp directly fed with 104,
105 or 106 CFU ml-1 transgenic EcN were determined by one-way ANOVA test. When
significant differences (P≤ 0.05) existed, the means were compared using the NewmanKeuls multiple comparison test. GraphPad Prism was used (GraphPad Software, Inc., San
Diego, CA) to perform statistical analyses.

RESULTS
In Trial 1, in which L. vannamei were fed paratransgenic Artemia engorged with
DB3-expressing EcN for 18 d, L. vannamei gut extracts showed a progressive increase in
signal of the recombinant antibody, DB3, from day 2 of feeding to day 21. Rapid
decrement in signal was noted on day 22, four days after the start of the washout period;
this reached undetectable levels on day 30 (Fig. 9). Bacteriology of the same gut extracts

Figure 9. Progesterone-binding activity of gut
extracts of shrimp. Shrimp were fed
paratransgenic Artemia engorged with DB3producing E. coli or fed Artemia engorged with
nontransgenic E. coli per the trial 1 protocol.
The arrow (d 19) indicates the start of wash-out
period where the feeding of wild type or
partransgenic Artemia was stopped. Values
are represented mean ± SEM (n-3).
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showed a progressive increase in CFU counts of DB3 producing- EcN during the active
feeding phase with a sharp decrease during the wash-out phase. CFU counts of transgenic
EcN reached a maximum in the shrimp gut on day 19 (3.8 x106 CFU gram-1) in L.
vannamei fed paratransgenic Artemia that were engorged with the transgenic bacteria
(Fig. 10A). Gut extracts of L. vannamei fed Artemia that were engorged with wild-type
EcN showed no change in CFU counts of transgenic bacteria (Fig. 10B).

Figure 10. Total colony forming units from the shrimp gut fed with paratransgenic
Artemia during 30 d feeding according to the trial 1 protocol. Total CFU and
Kan+Amp+CFU in shrimp fed transgenic E. coli engorged Artemia (A). Total CFU and
Kan+Amp+ CFU in shrimp fed wildytype E. coli engorged Artemia (B). The arrow (d 19)
indicates the start of wash-out period.

To study the quantitative transfer and bioaccumulation of proteins in shrimp gut via
Artemia, we conducted Trial 2 and quantified the accumulation of GFP-expressing EcN
via ELISA in both Artemia and L. vannamei gut. Accumulation of GFP in Artemia gut
was noted during the 10-hour feeding period. After 2 h, a concentration of 4.7 ± 1.2 ng
GFP per gram of Artemia gut was achieved, which then reached a peak value of 12.5 ±
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1.6 ng GFP g-1 after 8 hours. At 10 hours, a slight decrease was noted to 10.4 ± 0.3 ng
GFP g-1 (Fig. 11).

Figure 11. Quantity of GFP in the
paratransgenic Artemia gut fed with
transgenic GFP expressing E. coli fed at
a rate of 106 CFU ml-1 for 10 h.

We then fed to shrimp the Artemia engorged with transgenic EcN (6-8 h of
engorgement) at a rate of 20 or 40 Artemia per shrimp daily for 7 days followed by a 5
day wash-out. We quantified the GFP content per gram of shrimp gut by ELISA. Shrimp
PL‟s fed with 20 Artemia per day accumulated 36.3 ± 2.8 ng GFP per gram of shrimp gut
on day 5. Subsequently, GFP levels declined and at the last day of the wash-out phase
(day 7), levels dropped to 10.2 ± 0.8 ng GFP g-1 (Fig. 12). L. vannamei PL‟s fed with 40
Artemia per day accumulated 41.6 ± 0.8 ng GFP g-1 on day 3 (Fig. 12). On the last day of
the wash-out phase, levels decreased to 11.9 ± 0.9 ng GFP g-1. Although our statistical
analysis shows that GFP levels in shrimp fed 20 or 40 Artemia per day were not
significantly different, the shrimp fed 40 Artemia per day accumulated 10-15% more
GFP during the initial 3-4 h of feeding.
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Figure 12. Quantity of GFP in the shrimp gut fed
daily with paratransgenic Artemia (at a rate of 20
or 40 Artemia per day) engorged with GFP
expressing E. coli. The data are averages ± SEM
from two treatments. The arrow (d 7) indicates the
start of wash-out period.

In Trial 3, we fed transgenic bacteria (104, 105 and 106 CFU ml-1) directly to
shrimp to quantify GFP accumulation. In shrimp fed 106 , 105 and 104 CFU ml-1, the
shrimp gut accumulated 32.2 ± 0.7, 19.2 ± 1.2 and 13.7 ± 1.6 ng GFP per gram shrimp
gut, respectively. By day 6 and thereafter there was a slow decline in the GFP content to
the last day of the wash-out (Fig. 13).

Figure 13. Quantity of GFP in the shrimp gut
fed directly with GFP-expressing transgenic
E. coli at 104, 105, or 106 CFUml-1. The arrow
indicates the beginning of wash-out phase.
Values are represented mean ± SEM of three
parallel treatments.

Pair wise comparison of GFP content from shrimp fed with104 CFU ml-1 and 105
CFU ml -1was not significantly different at any timepoint. However, GFP accumulation in
shrimp fed with 106 CFU ml-1 was significantly higher than in shrimp fed with 104 CFU
ml-1 or 105 CFU ml-1. However, during the intial feeding days (d 3), shrimp gut
accumulated higher levels of rGFP (~40 ng GFP g-1) via feeding through Artemia that
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were engorged with rGFP-expresssing bacteria than feeding directly with transgenic
bacteria at a rate of 106 CFU ml-1 (~30 ng GFP g-1).
We also assessed the bacterial flora in shrimp before and during the period of
feeding with transgenic bacteria. Our results show that almost 97% of L. vannamei gut
bacteria after 6 d of active feeding were transgenic, with both genotypic and phenotypic
evidence of carbenicillin resistance and GFP production (Table 2). Therefore, active
feeding using transgenic bacteria can easily displace the inherent native flora in the
shrimp gut. However, at the end of the washout phase, the transgenic bacteria represent
only 35% of bacterial flora suggesting the interference of other bacterial flora in the
shrimp gut.

Table 2. Quantitative change in bacterial phenotype in
shrimp gut that were fed bacteria transgenic for
carbenicillin (Car+) resistance gene. The shrimp were
fed 106 EcN+Car+ GFP CFU ml-1 for 6 days followed by
6 days of wash-out phase.
Analysis Day
(colonies analyzed)

1

EcN+Car+ GFP+ (%)

0 (30)
0
1 (35)
80
6 (35)
97
12 (34)
35
1
+
Car = colonies resistant to carbenicillin
EcN+Car+ GFP+ represents the transgenic bacteria fed to shrimp
DISCUSSION
To optimize the delivery of recombinant proteins to shrimp larval stages, we
conducted a long term feeding trial for 30 days in which first 18 days we fed Artemia that
were engorged with transgenic EcN expressing DB3, a marker antibody followed by 12day washout period. Our results showed that both transgenic bacteria and antibodies
49

accumulated in the shrimp gut during the active feeding phase. However, the recombinant
proteins as well as transgenic bacteria depleted during the wash out phase suggesting a
tunable recombinant accumulation system. Hence, we report a practical paratransgenic
delivery of bioactive recombinant molecules to the commercial white shrimp, L.
vannamei. Using a bioamplification pathway derived from natural aquatic food systems,
we have demonstrated the accumulation of both a marker molecule and a functional
antibody in the gut of L. vannamei, the site of transmission of many marine pathogens,
such as Vibrios. This approach establishes a foundation for future applications that
deploy anti-microbial peptides and anti-viral antibodies in settings of commercial
mariculture.
As there was a possibility of directly using transgenic bacteria for shrimp feeding
purpose, we also determined the protein accumulation in shrimp larval stages fed directly
with transgenic bacteria compared to shrimp fed with Artemia engorged with the
transgenic bacteria in short-term feeding trials. Our results show that shrimp larvae had
higher recombinant protein accumulation that was fed with Artemia engorged with
recombinant proteins during the initial 3-4 days of feeding. This trend was more obvious
with shrimp that were fed with 40 Artemia per day. Since in commercial shrimp
hatcheries the normal Artemia feeding rate is 10-50 Artemia per shrimp per day, the
paratransgenic protein delivery using Artemia can be adapted to shrimp hatchery
operation.
In shrimp hatcheries, the infection due to Vibrio strikes at early stage PL‟s, 3-5
days post moulting (Brock and Lightner, 1990). The accumulation of recombinant antivibrio molecules or neutralizing antibodies in shrimp larvae against Vibrio in the first 3-4
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days using Artemia delivery might be a viable and practical method to reduce the Vibrio
infection in shrimp larval stages. In Artemia fed and in direct transgenic bacteria fed PL
shrimp, the levels of recombinant proteins in shrimp gut tended to decrease before the
wash-out phase began, suggesting a mechanism of degradation. The shrimp larval stages
develop an active digestive system during the phase between PL15 to juvenile stage.
These ontogenetic events are accompanied by significant changes in metabolic rates and
digestive enzyme activities (Lovett and Felder, 1990; Lemos et al., 1999). The digestive
system consists of highly active proteinase enzymes with proteolytic function for
degrading food particles (Lemos et al., 2000). The depletion in recombinant protein level
in shrimp gut during the 5th day might be due to activitiy of shrimp digestive enzymes on
recombinant proteins.
EcN is a well-studied probiotic bacterium and has been reported to colonize and
establish itself in the human intestine not only by its ability to produce adhesions,
microcins and sidereophores (Blum-Oehler et al., 1995, Boudeau et al., 2003), but also by
adhesion to the epithelial cells and mucus via type-1 and FIC fimbriae. Also, EcN
possesses unique systems for iron uptake, enhancing its vitality of fitness and competitive
advantage over other microflora of host. We assessed the use of direct transfer
recombinant proteins using EcN expressing GFP. Shrimp larval stages that were fed with
106 cfu/ml transgenic bacteria accumulated recombinant proteins in shrimp gut,
supporting the direct use of transgenic bacteria for protein delivery. Further, even within
1 day of feeding almost 80% of shrimp bacteria were transgenic bacteria, demonstrating
the efficacy of this EcN to displace the natural bacterial flora in shrimp gut. However,
even though EcN is regarded as probiotic, the direct use of transgenic bacteria in culture
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water might pose environmental issues related to the use of transgenic bacteria in
aquaculture operations (Dunham, 2009). Hence, Artemia engorged with recombinant
proteins might be better protein delivery systems to shrimp for paratransgenic approach.
Transfer of recombinant proteins through the food web has been studied in
transgenic crops to evaluate the effect of a recombinant toxin on arthropod pests.
Cry1Ab, a toxic protein expressed, in transgenic rice plants accumulated in the brown
planthopper, Nilaparvata lugens, a common pest arthropod in rice fields. Subsequently,
the protein was transferred to the wolf spider, Pirata subpiraticus, a predator of the
planthopper, demonstrating that recombinant proteins from a primary source organism
can accumulate at higher levels in the food chain (Chen et al., 2005, 2009). Because of
the degradative nature of digestive systems, at least two criteria must be met for
successful biotransfer of recombinant molecules. First, the feeding organisms should be
prolific feeders. Second, the prey-predator feeding time interval should be very short.
Both of these conditions are met in the food web comprised of bacteria (or algae),
Artemia and shrimp larvae. Non-specific filter feeding by larval stages of Artemia and
shrimp facilitates the biotransfer of proteins within the food chain. Furthermore, the
larval digestive systems in the initial stages in both Artemia and shrimp are
underdeveloped, thus reducing the deleterious effects of digestive enzymes on
recombinant proteins.
Shrimp mariculture is a vital economic activity in many countries and involves
intensive cultivation in confined environments that results in outbreaks of lethal viral and
bacterial diseases. Prophylactic use of antibiotics in aquaculture is banned worldwide due
to the emergence of antibiotic-resistant microbes. Hence, novel strategies to prevent
52

deadly outbreaks are needed to reduce the estimated $3 billion in annual losses due to
shrimp diseases. Several approaches involve boosting the nutritional value of Artemia
through bioencapsulation. Disease protection has been demonstrated using antibacterial
agents like trimethoprim-sulfamethoxazole in Artemia nauplii (Chair et al., 1996).
Furthermore, feeding of pre-formed molecules such as antibodies has proved efficacious.
A high affinity monoclonal antibody (MAb 216) directed at VP28, the anchor protein of
White Spot Syndrome Virus (WSSV) that facilitates viral entry in the cytoplasm of
shrimp cells (Yi et al., 2004), resulted in an 80% survival benefit when fed to shrimp that
were subsequently challenged with WSSV (Dante et al., 2007). Similarly, antiviral
peptides such as PmAV (Penaeus monodon antiviral) have been reported from WSSVresistant P. monodon (Luo et al., 2007). Vibrios, a group of bacteria with devastating
impact on shrimp and shellfish industries worldwide. Engineered lines of bacteria and
algae expressing PmAV, anti-VP28 single-chain antibodies and cationic peptides that are
fed to Artemia and, possibly, directly to shrimp could be developed to protect
commercial shrimp against White Spot Syndrome Virus infection and Vibriosis.
Bioaccumulation of these protective molecules in shrimp such as L. vannamei via the
paratransgenic approach holds great promise to address myriad diseases in shrimp
mariculture.
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CHAPTER 4
ANTIMICROBIAL ACTIVITY OF CATIONIC PEPTIDES AGAINST
PATHOGENIC MARINE VIBRIO SPP. OF FISH AND SHELLFISH
This chapter is based on the following article:
Subhadra, B., 2011. Antimicrobial Activity of Cationic Peptides against Pathogenic
Marine Vibrio spp. of Fish and Shellfish. Aquaculture (under preparation).
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SUMMARY
The activity of cationic peptides - apidaecin, cecropin, magainin, melittin and
moricin- was tested against pathogenic Vibrio spp. and probiotic feed organisms of
shrimp, to identify molecules for use in a paratransgenic control strategy against
Vibriosis in commercial shrimp culture. Moricin was the most potent antimicrobial agent
against Vibrio spp. with a minimum bactericidal concentration (MBC) in the 0.04-0.31
µM range. Cecropin and melittin killed Vibrios in the MBC range of 0.02-17.5 and 2.510.0 µM, respectively. Probiotic bacteria and algal feed organisms displayed high levels
of resistance toward cecropin and melittin suggesting that they would be suitable for a
paratransgenic approach to Vibriosis. A combination of 0.01 µM cecropin and 0.31 µM
melittin was bactericidal against Vibrio spp. demonstrating synergistic activity.
Independent clones of Vibrios evolved resistance to melittin over 80 passages that
spanned 500-600 generations, but resistance did not develop in Vibrio strains exposed to
a combination of cecropin and melittin at concentrations of 0.01 µM. Cecropin and
melittin exerted potent and synergistic activity against pathogenic Vibrios with no
toxicity toward probiotic or algal feed organisms. A combination of 1 μM cecropin and 1
μM melittin produced significant protection of Artemia against Vibrio campbellii in in
vivo challenge studies. Paratransgenic delivery of cationic peptides that target Vibriosis
in shrimp via feed organisms could offer powerful tools to increase protein food supply.
KEY WORDS: Antimicrobial peptides, Vibriosis, cecropin, melittin, paratransgenesis,
shrimp diseases
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INTRODUCTION
Vibriosis is a major shrimp disease which affects both hatchery and grow-out
phase of production. The term Vibriosis describes a spectrum of diseases and includes
oral and enteric Vibriosis, appendage and cuticular Vibriosis, localized Vibriosis of
wounds, shell disease, systemic Vibriosis and septic hepatopancreatitis (Brock and
Lightner, 1990). Outbreaks may occur when environmental factors trigger the rapid
multiplication of bacteria usually tolerated at low levels within shrimp blood (Sizemore
and Davis, 1985; Soto-Rodriguez et al., 2003), or by bacterial penetration of host barriers.
Here, we explore the application of paratransgenic strategies to vibriosis in
shrimp. In this strategy, commensal or symbiotic bacteria found at mucosal sites of
pathogen transmission are isolated and genetically altered to elaborate immune peptides
or engineered single chain antibody fragments that neutralize infectious agents. The
transgenic bacteria are then delivered back to mucosal sites where disease transmission
occurs (Durvasula et al., 1997). To apply this paratransgenic strategy to farmed shrimp,
we proposed a modified paradigm that involves microbes that are frequently used as feed
for marine animals (Durvasula et al., 2006). This is particularly important as one of the
main portals of entry for Vibrios is the midgut (Lovett and Felder, 1990). Oral acquisition
of pathogenic Vibrios through infected food sources is an important factor in the
pathogenesis of these bacteria (Lavilla-Pitago et al., 1998).
We recently demonstrated that Artemia fed transgenic lines of Synechococcus
bacillarus and Escherichia coli Nissle accumulated recombinant proteins that retained
biological activity for up to 10 h. These feed organsisms were used for paratransgenic
delivery of bioactive recombinant molecules to the commercial white shrimp, L.
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vannamei (results from Chapter 3). We hypothesize that such a system could be used to
deliver to farmed shrimp and fish foreign proteins with vibriocidal activity. In the present
study, we aim to identify specific peptides with potent bactericidal activity against marine
vibrios as well as bacteria which can potentially be used as paratransgenic vehicle to
express antibacterial peptides
Cationic peptides such as cecropin, apidaecin, magainin and melittin, which are
part of natural innate immunity in many invertebrate organisms (Zasloff, 2002), could
serve as effector molecules in a marine paratransgenic strategy to control Vibriosis.
These antibacterial peptides are very potent, with their inhibitory concentration being at
submicromolar or low micromolar range for neutralizing a variety of Gram- negative
bacteria, including some antibiotic resistant strains (Stark et al., 2002). The majority of
these peptides act through disintegrating the bacterial membrane or interfering with
membrane assembly (Hancock, 1997), with the exception of apidaecin which deactivates
a bacterial protein in a stereospecific manner (Otvos, 2000). We had previously
demonstrated the effectiveness of cecropin A and other AMP‟s in controlling
Trypanosoma cruzi via a paratransgenic approach (Durvasula et al., 1997; Fieck et al.,
2010). This study examines the in vitro activity of five antimicrobial peptides against
various Vibrio spp., as well as against bacteria and algae candidates for expressing these
molecules as paratransgenic vectors. We also studied the evolution of resistance against
single cationic peptide treatments and report here that a combination of cationic peptides
can avoid emergence of resistance in V. harveyi, V. penaeicida, and V. campbellii, the
three most important shellfish pathogens.
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MATERIALS AND METHODS
Bacterial strains, Culture media and Growth conditions
The sources of bacterial and algal cultures and their culture conditions are described in
Table 3.

Table 3. Sources and culture conditions of various bacterial and algal cultures used in
this study.
Bacteria and Algae
Strain, Source or Reference
Culture
conditions
Vibrio alginolyticus
ATCCa-19108
MBe at 30°C
b
V. alginolyticus
CAIM 516
MB at 30°C
V. anguillarum
90-11-287 Dr Lone Gram (Skov et al., 2001) MB at 30°C
V. campbellii
CAIM 519
MB at 28°C
V. ordalli
CAIM 608
MB at 30°C
V. harveyi
ATCC-BAA 1120
MB at 30°C
V. harveyi
CAIM 513
MB at 30°C
V. harveyi
BW106, Dr A. Parvathi, NIO, India
MB at 30°C
V. parahaemolyticus
CAIM 320
MB at 32°C
V. parahaemolyticus
BW108 Dr A. Parvathi, NIO, India
MB at 32°C
V. penaeicida
CAIM 285
MB at 28°C
V. furnissi
BW105 Dr A. Parvathi, NIO, India
MB at 32°C
Bacillus megaterium
WH320 (MolBioTech Inc., Germany)
BHIf at 30°C
B. subtilis
ATCC-128 Dr D Delfina (UTEP, Texas)
BHI at 30°C
B. subtilis
ATCC-6051 Dr D Delfina (UTEP, Texas)
BHI at 30°C
Brevibacterium linens
Durvasula lab- Eg 1, Hillesland et al. (2008) LBg at 30°C
Synechococcus bacillarus
CCMPc-1333
f/2h at 25°C
Dunaliella salina
UTCCd- 197
f/2 at 25°C
a

American Type Culture Collection (ATCC)
Collection of Aquatically Important Microorganisms, CIAD, Mexico.
c
Provasoli-Guillard National Center for Culture of Marine Phytoplankton, USA
d
University of Toronto Culture Collection
e
MB: Marine Broth (Sizemore and Stevenson, 1970), Difco 2216, BD Biosciences, Sparks, MD, USA
f
Brain Heart Infusion Broth (Sambrook et al., 2000), EMD Chemicals, Gibbstown, NJ, USA
g
Luria-Bertani Broth (Sambrook et al., 2000), EMD Chemicals, Gibbstown, NJ, USA
h
f/2 media (Guillard, 1975), Sigma-Aldrich, St Louis, MO, USA.
b

Antimicrobial Peptides
Apidaecin (GNNRPVYIPQPRPPHPRL), cecropin A (KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAL), magainin II (GIGKFLHSAKKFGKAF58

VGEIMNS), moricin (AKIPIKAIKTVGKAVGKGLRAINIASTANDVFNFPKPKKRK),
and melittin (GIGAVLKVLTTGLPALISWIKRKRQQ) were chemically synthesized
(Biosynthesis Inc. USA and GeneScript Corporation, USA). The peptides were dissolved
as 1 mM stock solutions in phosphate buffered saline (137mM NaCl, 2.7 mM KCl, 10
mM phosphate buffer, pH 7.2-7.4 at 25ºC) containing 0.01% BSA. The stock solutions
were filter sterilized and stored at -80oC.
Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration
(MBC) Determinations
The MIC and MBC were determined using a modified microbroth dilution
protocol on 96-well plates (Wiegand et al., 2008). One row of a sterile 96 well plate was
used for each bacterial isolate tested with up to 12 serial dilutions of the antibacterial
peptide (column 1-12). Hundred micro-liters of sterile media were added to columns 212. The 1 mM stock solution of antimicrobial peptide was diluted 1:50 by adding 4 μl of
the stock to 196 μL of LB broth in column-1 to obtain a final peptide concentration of 20
μM. A two-fold serial dilution of the peptide was achieved in columns 2 to 12 by adding
100µl to the next well of the microplate. Each well was then inoculated with 100 μl of
test culture, suitably diluted to adjust the final cell density to 2 - 5 × 105 colony forming
units (CFU) ml -1. The plates were incubated for 18-24 h at the optimum temperature for
each bacterial species (Table 3). For algal cultures, the plates were incubated at 72 h at
25°C at constant illumination. For this work, we defined minimum inhibitory
concentration (MIC) to be the lowest AMP concentration that would reduce cell growth
by more than 50% as determined by OD600 readings, while minimum bactericidal
concentration (MBC) was defined as the lowest concentration of each peptide that
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resulted in no growth on agar plates (24 h incubation) following treatment when
compared to control (NCCLS, 2004). These experiments were performed in duplicate and
repeated twice.
Antimicrobial Combination Studies
Two AMP combinations: cecropin + melittin (Cec + Mel) and melittin +
magainin (Mel + Mag), were tested against Vibrio campbellii CAIM 519, V. harveyi
CAIM 513, and V. penaeicida CAIM 285. Concentrations of 0.01, 0.03, 0.16, and 0.31
µM of the antimicrobials were used in the combination experiments. The selected
concentrations of AMP‟s for combination studies were well below (10-50 fold less) the
MBC‟s of the target organisms. The MBC and MIC of the Vibrio strains before and after
selection in melittin were determined as described in the previous section.
Experimental Evolution of Resistance against Melittin or Peptide Combinations
This experiment was performed as a modified protocol of Perron et al., (2006).
Here, we evaluated the ability of three virulent Vibrio spp., Vibrio campbellii CAIM 519,
V. harveyi CAIM 513, and V. penaeicida CAIM 285, to grow in increasing
concentrations of melittin. We established three independent clones of each test strain.
Mid-log phase cells of each strain were diluted 1:200 in fresh marine broth (MB) in the
absence of melittin on a 96 well plate and allowed to grow overnight at 30oC. Cells from
each well were maintained by daily passage, using the same dilution, into a fresh plate.
At the 11th passage, a sub-MBC dose of melittin, 1.0 µM, was added to each well. This
AMP concentration was maintained for 10 subsequent passages. Afterwards, we doubled
the concentration of melittin at every tenth transfer. With each increase in melittin
concentration, a 100 µl sample of the cells was inoculated in 25% glycerol in LB or MB
60

broth and stored at - 80 °C. A total of 80 serial passages were performed, consisting of
approximately 500-600 generations of Vibrio growth, to a highest melittin concentration
of 128 µM. We selected 128 µM as the final concentration because melittin has a
tendency to precipitate at higher concentrations in MB (Raghuraman and Chattopadhyay,
2007) and because 128 µM was 1-2 orders of magnitude higher than the MBC‟s of
melittin against Vibrio strains. Cell growth was monitored daily by OD600 on a microtiter
plate reader. The MBC and MIC of the glycerol cultures were determined as described
previously. We then repeated the above experiment using a combination of two AMP‟s.
Cells from independent colonies from each of the three Vibrio strains were grown in 0.01
µM of cecropin and 0.01 µM of melittin. Cells were passaged as described.
Axenic Hatching of Artemia
All experiments were performed with cysts of A. franciscana (BrineShrimp
Direct, Ogden, UT). Sterile nauplii were hatched via the de-capsulation method. Briefly,
two hundred milligrams of cysts were hydrated in 18 ml tap water for 1 h with gentle
shaking and sterile aeration. Six hundred and sixty μl of freshly prepared NaOH (32%)
and 10 ml of NaOCl (50%) were added to the hydrated cyst suspension, and the reaction
was stopped after 2 min by adding 14 ml of Na2S2O3 (10g l-1). The de-capsulated cysts
were washed twice with sterile seawater and re-suspended in a 50 ml tube containing 30
ml of sterile seawater prepared by dissolving 35 g ocean salt per liter distilled water. The
cysts were then allowed to hatch at 28ºC with constant illumination for 24-28 h on a
rotor. After hatching, groups of 20 nauplii were transferred to new sterile 50 ml tubes that
contained 20 ml of sterile seawater. The axenic state of the Artemia was confirmed for
each hatching trial by culturing a 3 ml sample of Artemia in fresh MB Broth for 2 days at
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28ºC followed by observance of growth of any bacterial colonies. Nauplii from hatching
trials with positive aerobic bacterial growth on MB were discarded.
Antimicrobial Immersion-treatment of Artemia
A cecropin and melittin combination was selected as the antimicrobial treatment
based on our in vitro results. Combination treatments of cecropin and melittin at 5 μM
and 1μM of each peptide in PBS were prepared. Single treatments of cecropin and
melittin of 1 μM were also included as controls. Batches of 100-120 Artemia were
immersed in peptide suspensions (treatment) or PBS (control) for 2 h prior to Vibrio
challenge trials.
Vibrio Challenge Studies
All manipulations were performed under laminar flow to maintain the sterility of
Artemia cysts and nauplii. Twenty healthy Artemia nauplii were selected from the
immersion treatments and added to each of four 50 ml tanks. We selected Vibrio
campbellii CAIM 372, a highly pathogenic strain to Artemia (Soto-Rodriguez et al.
2003), for the challenge studies. Our preliminary studies showed that V. campbellii
CAIM 372 at a concentration of 107 ml-1 of culture water killed over 70-75% of Artemia
in 12 h. Artemia in all tanks were exposed to V. campbellii CAIM 372 at a concentration
of 107 CFU ml-1 for 12 h. A control tank was established with Artemia and no Vibrio
inoculation. Since we will ultimately express antimicrobial petides via probiotic agents
such as Bacillus subtilis, we added autoclaved B. subtilis 0179 (Lallemand Inc, Canada)
once at the start of the experiments at a dose of 106 CFU ml-1. Artemia tanks containing
autoclaved B. subtilis with no prior antimicrobial peptide immersion were also used as
controls. Mortality rates of the Artemia were recorded at 12 h post-challenge. The
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experiment was repeated once. The quantitative Vibrio load in Artemia was determined
by taking samples from the challenge trial tubes at 2, 4, 8 and 12 h. Artemia were
suspended in 1 ml PBS and tissue was disrupted using sterile needles before final resuspension in 10 ml of sterile PBS. Serial dilutions of this suspension were made
followed by triplicate plating on LB agar. After overnight incubation colonies were
counted. Results were presented as CFU per Artemia.
Statistical Tests
In AMP evolution of resistance studies the means of three clones before selection
were the same, therefore we conducted a Wilcoxon signed rank test (P≤ 0.05) (GraphPad
Software, Inc., San Diego, CA). In Vibrio challenge trials quadruplicate tubes served as
the experimental units in all statistical analysis. The survival data from challenge trial
were subjected to Students t test, and a p≤ 0.05 was considered significant. A statistical
software GraphPad Prism was used (GraphPad Software, Inc., San Diego, CA) to
perform this analysis.

RESULTS
Activity of Antimicrobial Peptides against Vibrio spp. and Probiotic bacteria
Moricin was the most potent anti-bacterial agent against all Vibrio spp. tested,
with MBC and MIC ranging from 0.04-0.313 µM and 0.005-0.01 µM, respectively
(Table 4). The MBC of cecropin ranged from 0.02-17.5 µM. Different strains of a similar
Vibrio spp. demonstrated significant differences in susceptibility toward the peptides. For
example, Vibrio harveyi ATCC-BAA-1120 was highly sensitive to cecropin
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Table 4. Minimum bactericidal concentration (MBC) and minimum inhibitory concentration (MIC) of different
cationic peptides against bacterial and algal species (µM).

AMP
Bacteria /Alga tested
Vibrio spp.
V. alginolyticus ATCC-19108
V. alginolyticus CAIM 516
V. anguillarum 90-11-287
V. campbellii CAIM 519
V. campbellii CAIM 372
V. ordalli CAIM 608
V. harveyi ATCC-BAA 1120
V. harveyi CAIM 513
V. harveyi BW106
V.parahaemolyticus CAIM320
V. parahaemolyticus BW108
V. penaeicida CAIM 285
V. furnissi BW105

Apidaecin
MBC

Cecropin A

Magainin

MIC

MBC

MIC

Melittin
MBC

MIC

Moricin

MIC

MBC

MBC

MIC

>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20
>20

10
5
10
5
10
5
5
5
5
10
5
10

1.3
2.5
5
2.5
10
0.02
1.3
2.5
2.5
10
17.5
5

0.15
0.31
0.02
0.31
0.63
5
0.01
0.04
0.31
0.31
2.5
12.5
1.3

10
15
>20
7.5
10
7.5
>20
>20
>20
>20
>20
7.5

2.5
5
2.5
2.5
5
2.5
2.5
5
2.5
2.5
2.5
1.3

2.5
5
5
2.5
1.3
10
5
5
10
10
10
10
10

0.01
1.25
1.25
0.63
0.31
2.50
0.01
0.01
2.5
1.25
2.5
2.5
2.5

0.31
0.31
0.31
0.04
0.04
0.01
0.31
0.63
0.31
0.63
0.31
0.31

0.01
0.01
0.01
0.01
0.01
<0.01
0.01
0.31
0.01
0.04
0.01
0.01

>20
>20
>20
>20

10
15
10
>20

1.3
10
>20
>20
>20

0.01
5
10
15

2.5
>20
>20
>20

0.31
5
5
>20

0.31
>20
>20
>20

0.01
5.0
5.0
10.0

0.04
2.5
2.5
5

0.01
0.63
0.63
1.3

>20
>20

10
10

12.5
>20

>20
>20

15
>20

>20
>20

5.0
>20

2.5
10

0.63
2.5

Probiotic bacteria
Bacillus megaterium WH320
B. subtilis 168
B. subtilis 6051
Brevibacterium linens Eg

Algal species
Synechococcus bacillarus
Dunaliella salina

>20
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with an MBC of 0.02 µM. However, V. harveyi CAIM 513, a strain isolated from
diseased fish and shellfish, had an MBC that was approximately 63-fold higher. The
bactericidal concentrations of melittin against all the Vibrio spp. tested were rather
consistent, with most strains succumbing within the range of 5-10 µM. V. penaeicida,
another strain that was isolated from diseased shrimp, appeared to be resistant to all the
anti-microbial peptides tested. None of the Vibrio spp. appeared susceptible to even 20
µM apidaecin.
Apidaecin, cecropin, magainin, and melittin had minimal effect on Bacillus
subtilis 6051 and Brevibacterium linens indicating that these strains might be used to
express cecropin and melittin against Vibrios in a paratransgenic approach. The MBC for
all the antimicrobial agents tested against these two microbes was greater than 20 µM.
Again, the tolerance to each AMP was strain dependent. The MBC for cecropin was 10
µM in B. subtilis 168. Moricin was the only peptide that was bactericidal (5 µM) against
Brevibacterium linens, and B. megaterium WH320, a non-spore forming species, had
very low MBC and MIC values for all the cationic peptides used in these experiments
(Table 4).
Activity of Antimicrobial Peptides against Marine Algal Species
Moricin was the only peptide with algicidal activity against Synechococcus
bacillarus and Dunaliella salina with an MIC of 0.63 and 2.5 µM, respectively (Table 4).
These two algal species appeared to be resistant to the other antimicrobial peptides tested
again indicating that these algal strains may be used to express cecropin and melittin in a
paratransgenic approach.
65

Antimicrobial Combination Studies against Vibrio spp.
The MBC‟s of melittin and cecropin for Vibrio harveyi CAIM 513 were 1.3 and 5
µM, respectively (Table 4). However, when used in combination, concentrations as low
as 0.01 µM cecropin and 0.16 µM melittin exerted bactericidal effect against V. harveyi
CAIM 513 and V. campbelli CAIM 519. Similarly, a combination of 0.01 µM cecropin
and 0.31 µM melittin was bactericidal against V. penaeicida CAIM 285 (Table 5).
Magainin and melittin combination studies showed that a combination of 0.31 µM of
each peptide was bactericidal against the three strains tested. These results suggest that
combinations of AMP‟s are highly synergistic against Vibrio spp. The concentrations of
AMP‟s required for vibriocidal activity against all three Vibrio spp. were well below the
MBC values of cecropin and melittin individually (Table 5).
Table 5. The lowest concentration of antimicrobial peptides in combination that
demonstrated bactericidal effect against pathogenic Vibrio strains.
Vibrio spp.
Cecropin/Melittin
Melittin/Magainin
mixture (µM, each)
mixture (µM, each)
Vibrio campbellii CAIM 519
Vibrio harveyi CAIM 513
Vibrio penaeicida CAIM 285

0.01/0.16
0.01/0.16
0.01/0.31

0.31/0.16
0.31/0.31
0.31/0.31

Experimental Evolution of Resistance in V. campbellii, V. harveyi, and V. penaeicida
Toward Melittin
Progressive selection in increasing concentration of melittin for 500-600
generations of the pathogenic Vibrios resulted in cells that were significantly more
resistant to this AMP when compared to the progenitor culture, suggesting the emergence
of resistance. While no change in the MBC was observed, a 200-fold increase in MIC
was noted in two of the melittin-selected Vibrio campbellii lines. All three melittin66

selected V. harveyi lines had significant increase in both MBC and MIC. Similarly the
melittin-selected V. penaeicida lines also demonstrated a 3-5 fold increase in the MBC
Table 6. Development of resistance to AMPs. Minimum bactericidal concentration
(MBC) and minimum inhibitory concentration (MIC) of Vibrio penaeicida CAIM 285,
Vibrio harveyi CAIM 513 and Vibrio campbellii CAIM 519 clones before and after
selection for experimental evolution of antimicrobial resistance against melittin.

Vibrio spp.
Vibrio campbellii, CAIM 519
Clone 1
Clone 2
Clone 3
Average
Vibrio harveyi, CAIM 513
Clone 1
Clone 2
Clone 3
Average
Vibrio penaeicida, CAIM 285
Clone 1
Clone 2
Clone 3
Average

Melittin before selection
MBC (uM)
MIC (uM)

Melittin after selection
MBC (uM)
MIC (uM)

2.5
2.5
2.5
2.5 ± 0.0

0.63
0.63
0.63
0.63 ± 0.0

10.0
5.0
5.0
6.7 ± 1.7

2.5
1.0
1.0
1.5 ± 0.5*

5.0
5.0
5.0
5.0 ± 0.0

0.005
0.005
0.005
0.005 ± 0.0

60.0
30.0
30.0
40.0 ± 10.0*

40.0
20.0
15.0
25.0 ± 7.6*

10.0
10.0
10.0
10.0 ± 0.0

2.5
2.5
2.5
2.5 ± 0.0

32.0
16.0
50.0
32.7 ± 9.8

15.0
10.0
20.0
15.0 ± 2.8*

* significant difference compared to values before selection. Variances are SEM.

values (Table 6). We were unable to generate any double-AMP- resistant cells of Vibrio
campbellii CAIM 519, V. harveyi CAIM 513 or V. penaeicida CAIM 285 to cecropin and
melittin. All three species died within three passages of being cultured in 0.01 µM of
cecropin and melittin, suggesting that combination therapy can prevent simultaneous
emergence of resistance against the two AMP‟s (data not shown).
Artemia Challenge Trials
Artemia treated with cecropin plus melittin at 1 μM or 5 μM and then challenged
with Vibrio campbellii 372 had significantly higher survival than Artemia treated with
PBS (Fig. 14). Artemia that were given either cecropin or melittin alone at 1 μM failed to
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enhance survival rates (data not shown). The control group of Artemia without Vibrio
challenge had 98.8 ± 1.2 percent survival which was similar, to the survival of Artemia
treated with cecropin plus melittin (5 μM) without Vibrio challenge (Fig. 14) indicating
absence of toxicity due to the AMPs. In the control group of Artemia that was challenged

Figure 14. Percentage survival of
Artemia treated with Cec + Mel (5 μM)
or control (phosphate buffered saline)
and infected with V. campbellii CAIM
372 for 12 h. Values are mean ± SEM, n
= 4. The symbols ** and *** represents
P <0.01 and P < 0.001, respectively.

with Vibrio campbellii without prior
antimicrobial treatment, the average V.
campbellii bacterial level reached 1.4 x 107CFU per Artemia 2 h post challenge.
Thereafter, average V. campbellii number per Artemia remained in the range of 2.2-5.3 x
107 up to 12 h post challenge (Fig. 15). Amongst Artemia treated with Cecropin and
Melittin (5 μM) and challenged with V. campbellii, the average V. campbellii bacterial
level reached 3.0 x 104 CFU/Artemia at 2 h post challenge and remained in the range of
1.9-3.9 x 104 CFU/Artemia up to 12 h post challenge. Amongst Artemia treated with Cec
+ Mel (1μM) and challenged with V. campbellii, the Vibrio load during the 2-8 h period
post challenge was approximately 2 logs lower than the control group; however in the
final 4 h post challenge the Vibrio load approximated that of controls (Fig. 15).
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.

Figure 15. V. campbellii (CAIM 372) colonization of Artemia treated with Cec + Mel
(cecropin and melittin) (5.0 μM) (filled triangles) or Cec + Mel (1.0 μM) (filled
rectangles) or control (Phosphate buffered saline) (clear rectangles) at 0, 2, 4, 8 and 12 h
post-challenge with V. campbellii.

DISCUSSION
In our assessment of the action of peptides against a variety of Vibrio strains and
larval feed organisms, moricin was the most potent antimicrobial peptide with MBC
values in the nanomolar range. However, moricin was lethal to Bacillus spp.,
Brevibacterium spp. and algal species, all feed organisms that would be required as a
platform for expression of anti-pathogen molecules. We have therefore excluded moricin
from further consideration in the marine paratransgenic strategy. Similar to this finding
Hara et al. (1994) earlier reported that moricin at a concentration range of 0.27-0.53 µM
had bactericidal activity against Gram negative and Gram positive bacteria such as E.
coli, Acinetobacter spp., Pseudomonas spp. and Staphylococcus aureus.
Cecropin and melittin were active against Vibrio spp. with bactericidal
concentrations in the micromolar range (5-10 µM). The use of these two peptides for
control of fish pathogens has been proposed previously (Kelly et al., 1990). Continuous
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delivery of CEME, a cecropin-melittin hybrid peptide, via an implanted mini-osmotic
pump in the peritoneal cavity of Coho salmon significantly reduced mortality in Vibrio
anguillarum-infected fish (Jia et al., 2000). However, the high cost of these synthetic
peptides, especially when delivered by continuous infusion, may be prohibitive.
Bacillus subtilis, Brevibacterium linens, Synechococcus bacillarus and Dunaliella
salina were resistant to cecropin and melittin with MBC values in the range of 10 to
greater than 20µM. Gram positive bacteria are generally more resistant to antimicrobial
peptides than Gram negative bacteria (Brogden, 2005). However, the Bacillus
megaterium strain we used in this study was highly susceptible to all the peptides tested.
We used B. megaterium WH320 strain which is asporogenic and was primarily
developed for bacterial transformation protocols (Rygus and Hillen, 1991). We did not
establish whether the asporogenic nature of this strain might have affected its
susceptibilities toward various peptides. Nevertheless, the susceptibility of this organism
to antimicrobial peptides eliminates it from further consideration in a paratransgenic
strategy. Magainin has been reported to be active against Gram negative and Gram
positive bacteria (Vaara, 2009) but we tested a version of this peptide that lacks amide
modifications and exhibited little activity. We, therefore, eliminate this peptide from
further paratransgenic systems. Apidaecin exhibited no activity (MBC >20 µM) against
all the bacterial and algal species tested. Our results contradict earlier reports that
apidaecin is very active against Gram-negative bacteria, especially Enterobacteriaceae
(Czihal and Hoffmann, 2009). The antimicrobial activity of apidaecin is primarily via
steric hindrance of bacterial proteins such as membrane transporters, thereby causing
disruption of key cellular functions (Castle et al., 1999). Possibly, the target proteins of
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apidaecin in Vibrio spp. are structurally different from those of other Enterobacteriaceae
rendering this peptide inactive against this genus. Though further studies into the
mechanisms of apidaecin are required, our initial screening shows that apidaeicin and
magainin are not ideal candidates for a paratransgenic approach.
The Vibrio strains used in our study exhibit a difference in susceptibility toward
the various antimicrobial peptides tested. Further, different isolates of each species show
evidence of varying susceptibility toward a given peptide. Antimicrobial peptides bind to
the surface of a cell membrane in a carpet like manner, thereby increasing permeability to
ions and other metabolites via pore formation (Brogden, 2005). It is possible that, though
related, the different Vibrio spp. we tested might have subtle changes in membrane
characteristics. Adaptation of bacterial membranes to changing environments using
amino-acylated phospholipids as a resistance mechanism to cationic antimicrobial
peptides has been described (Roy et al., 2009). Dramatic differences in MIC were also
observed in Pseudomonas aeruginosa on increasing one positive charge via charged
amino acid residue on the polar lipid bilayer (Hancock and Farmer, 1993). The Vibrio
strains used in this study had been isolated from diverse geographic areas and were likely
subjected to different environmental effects.
The pathogenic strains of Vibrio harveyi CAIM 513 and V. alginolyticus CAIM
516 which were isolated from diseased fish and shellfish had approximately 10-fold
higher resistance to antimicrobial peptides than the commercially available V. harveyi
ATCC-BAA 1120. Vibrio spp., V. harveyi in particular, isolated from shrimp farms are
more resistant to antibiotics compared to isolates from other environments (Vaseeharan et
al., 2005). Similarly Teo et al., (2002) identified several antibiotic resistance genes and
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plasmids from V. harveyi W3B, a marine isolate from a shrimp farm. Possibly, the V.
harveyi CAIM 513 strain used in this study used inherited antibiotic resistance genes and
gene products such as efflux pumps to partially eliminate antimicrobial peptides (Okusu
et al., 1996). This explanation might also hold true for V. penaeicida, which was one of
the most resistant Vibrio spp. in our study.
Emergence of resistant mechanisms in bacteria because of the pervasive and
indiscriminate use of antibiotics in aquafeed to prevent infections and promote growth
has been a major public health issue related to the sustainable production of animal foods.
Molecular mechanisms of resistance, which has been identified as a necessary component
of pathogenesis of certain bacteria, to antibacterial peptides have been identified in
several groups of bacteria (Yeaman and Yount, 2005). It has been reported that most
cationic peptides do not induce resistance mutants in vitro and enhance antimicrobial
activity of classical antibiotics thus serving as an anti-resistant compounds (Hancock,
1997). Since our paratransgenic approach uses antimicrobial peptides, concerns exist
about the public health consequence of drug resistance in the targeted microbes.
Therefore, we studied the evolution of resistance of Vibrio spp. in the presence of sublethal concentrations of melittin over several generations. Our results showed that the
MIC and MBC of Vibrio harveyi and V. penaeicida clones after exposure to low
concentrations of peptides were significantly higher than those of the parent clones,
confirming experimental evolution of resistance. Similarly, Escherichia coli and
Pseudomonas fluorescens acquired heritable resistance against pexiganan, an analogue of
magainin, when propagated with this antimicrobial peptide for 600-700 generations
(Perron et al., 2006). Likewise, V. anguillarum, V.vulnificus and Yersinia ruckeri
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exhibited an inducible resistance to cecropin B with reversible changes in their ultra
structure (Sallum and Chen, 2008).
The use of antimicrobial agents in combination is an effective method to slow
development of resistance in target organisms. None of the tested Vibrio isolates in this
study developed resistance against combination treatment with melittin and cecropin.
This might be due to several reasons. Cecropin and melittin have multiple mechanisms of
action such as disruption of the outer cell membrane, the cytoplasmic membrane and
direct targeting of nucleic acids (Zhang et al., 2000). When used in combination, 0.01 µM
cecropin and 0.16 µM melittin exerted full vibriocidal effect toward Vibrio harveyi
CAIM 513. A similar effect was noted with these two peptides against V. penaeicida
CAIM 285 and V. campbellii CAIM 519. Such synergism has been described in shellfish
as a natural phenomenon. Two peptides from Crassostrea gigas, a proline-rich peptide
and a defensin, are expressed exponentially and act synergistically to ward off pathogens
in the event of infection (Gueguen et al., 2009). Delivery of peptides with vibriocidal
activity in combination will permit synergistic killing of pathogenic Vibrios in the gut of
farmed marine animals while reducing the evolution of drug-resistant microbes. Indeed,
the very low concentrations of cecropin and melittin needed to kill otherwise drugresistant isolates such as V. harveyi CAIM 513 and V. penaeicida CAIM 285 in this study
suggest that paratransgenic expression and delivery of these peptides in the gut of
animals such as shrimp and fish is possible and merits further study under field
conditions.
To test the protective efficacy of these peptides in vivo, we conducted Vibrio
challenge trials on Artemia. A mixture of cecropin and melittin at a concentration as low
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as 1 μM partially protected Artemia against the highly pathogenic Vibrio campbellii
CAIM 372. Toxicity of the peptides toward Artemia was not observed, even at
concentrations of 5 μM. The protective effect of the peptides appears to be due to low
colonization of Vibrio as indicated by the significantly lower V. campbellii load in
Artemia samples treated with peptides during the initial 2-4 h after bacterial challenge.
Paratransgenic systems involve the differential activity of peptides toward the
targeted infectious agent and host bacteria that serve as a platform for expression of the
peptides (Durvasula et al., 1997). We have demonstrated concurrent delivery of multiple
populations of recombinant bacteria to the brine shrimp, Artemia franciscana and L.
vannamei (Chapter 2 and Chapter 3). Cecropin and melittin can be considered ideal for a
paratransgenic approach because of their lethal effects on Vibrio spp. and minimal
activity toward feed organisms of shrimp. In vitro experiments using these AMP‟s
demonstrate significant protective effects against pathogenic Vibrios, suggesting that
synergistic activities of very low concentrations of cecropin and melittin in the gut of
commercial marine animals, delivered via feed bacteria and algae either directly or
through Artemia, could offer a new tool in the control of infectious diseases in
commercial mariculture.
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CHAPTER 5
EXPRESSION OF MELITTIN IN BACILLUS SUBTILIS FOR MARINE
PARATRANSGENIC DISEASE CONTROL
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SUMMARY
The marine paratransgenic approach involves the expression of anti-infectious
molecules in feed algae or probiotic bacteria. Previous studies have shown that melittin
has antibacterial activity against pathogenic vibrios. The main objective of the present
study was to optimize melittin expression in B. subtilis as a step towards developing a
paratransgenic disease control strategy. The melittin gene was cloned into pHT01and
transformed into B. subtilis to generate B.subtilis- pHT01-Mel strains. Growth of
transgenic B. subtilis strains was similar to the wild type strain. The pHT01-based
plasmids were stable in B. subtilis with neglible plasmid loss during the 7 day study
without antibiotic selection. Transgenic B. subtilis pHT-Mel exhibited a low level of
melittin expression based on ELISA. Several strategies will be proposed in Chapter 6 for
further optimization of melittin expression in B. subtilis as well as algal species for
ultimate use as disease control paratrangenic agents.
INTRODUCTION
Recently, we explored the application of paratransgenic strategies to target
Vibriosis, one of the most devastating shrimp diseases caused by at least 14 species of
Vibrio (Brock and Lightner, 1990). To apply the paratransgenic strategy to farmed
shrimp, we proposed a modified paradigm that involves microbes that are frequently used
as live feed organisms for marine animals (Durvasula et al., 2006). We demonstrated that
Artemia -a common live feed organism- fed transgenic lines of Synechococcus bacillarus
and Escherichia coli Nissle accumulated recombinant proteins (GFP and marker single
chain antibodies) which retained biological activity for up to 10 h inside the gut
(Subhadra et al., 2010). This delivery system was also tunable in that accumulation of
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recombinant proteins in Artemia occurred only during the active feeding period with
rapid decrement in protein levels during a washout period (Subhadra et al., 2010). We
also screened potential anti-vibrio molecules and found that melittin, magainin and
cecropin, naturally occurring antimicrobial peptides that form part of innate immunity in
insects, have potential applications as anti-Vibrio agents as parts of a paratransgenic
strategy. These AMPs exhibited selective toxicity toward diverse strains of Vibrios with
minimal effect on feed bacteria and algae. Furthermore, when used in combinations, they
exhibit marked synergistic activity toward Vibrio spp. and appear to reduce evolution of
target bacterial resistance. As a next step in developing marine paratransgenic approach,
the present study was aimed at cloning, melittin -a potent AMP- into paratransgenic host
organisms (algae, Bacillus spp, cyanobacteria).
Melittin is the principal toxic component in the venom of the European honeybee,
Apis mellifera (Mackler and Kreil, 1977). It is a cationic, linear peptide composed of 26
amino acid residues (NH2- GIGAVLKVLTTGLPALISWIKRKRQQ-CONH2) in which
the amino-terminal region is predominantly hydrophobic whereas the carboxy-terminal
region is hydrophilic due to the presence of a stretch of positively charged amino acids
(Mackler and Kreil, 1977). Though melittin has a high proportion of non-polar amino
acids, it is highly soluble in water (>250 mg/ml) (Raghuraman and Chattopadhyay,
2007). Melittin is monomeric at low concentration and adopts essentially a random coil
conformation in aqueous solution. Aggregation of monomeric melittin to a tetramer is
promoted by high salt, high melittin concentration, and high pH.
Our earlier studies have shown that melittin was toxic against pathogenic Vibrio
spp. while selected strains of B. subtilis were resistant up to a concentration of 20 µM.
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Hence, we selected melittin as the anti-vibrio agent and B. subtilis as the host bacteria for
anti-vibrio expression platform for further developing the concept of marine
paratransgenesis. There are several advantages of using B. subtilis as host bacteria for
themarine paratransgenic approach. (i) B. subtilis is a well-known host for industrial
enzyme production (Ferreira et al., 2005); (ii) B. subtilis is nonpathogenic and regarded
as „generally recognized as safe‟ (GRAS); (iii) the strains have a capacity for secreting
recombinant proteins such as neutralizing antibodies in biologically active forms and can
serve as an oral vaccine carriers (Gat et al., 2003); (iv) it can grow in simple and
inexpensive media at fast rates for large-scale fermentation (Fu et al., 2008); (v) it is
highly amenable to genetic manipulations such as transformation and expression of
recombinant proteins (Nguyen et al., 2003); (vi) it has been extensively used in
aquaculture for better nutrient assimiliation, bioremediateion of nutrients in aquaculture
operations and for probiotic infectious disease control (Verschuere et al., 2001;
Nakayama et al., 2009). The main objective of the present study is to optimize melittin
production from B. subtilis to further develop the concept of the marine paratransgenic
infectious disease-control approach.

MATERIALS AND METHODS
Bacteria and culture media
Bacillus subtilis1012 (wild type: leuA8 metB5 trpC2 hsdRM1) was obtained from
Bacillus Genetic Stock Center (BGSC), and B.subtilis ATCC168 was a generous gift
from Dr D. Delfina (University of Texas, El Paso). Penessay broth 2X (1% peptone,
0.15% yeast extract, 0.15% beef extract, 600 mM sodium chloride, 0.1% glucose, 0.05
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mM potassium phosphate, pH 7.0) and 2x SMM (1M sucrose, 40 mM maleic acid, 40
mM MgCl2, pH 6.5) were sterilize by autoclaving for 12 minutes. SMMP (equal volumes
of 2x SMM and 2x Penessay broth) was prepared freshly before use.
Plasmid vector contruction and bacterial transformation
We selected pHT01 (MolBiotec, Germany) as the expression plasmid for melittin
expression. pHT01 is a high protein-expressing inducible vector with B.subtilis origin of
replication and chloramphenicol selection (Nguyen et al., 2005). For constructing
pHT01-GFP vector, GFP gene from pGFP was digested using Xba1 and ligated into
Xba1 site in pHT01 vector (Fig. 16). One hundred µl of the transformation

Figure 16. Schematic representation of
pHT01-GFP vector. GFP gene was cloned
downstream of the Pgrac promoter.

mixture were plated onto LB-carbenicillin agar selection plates and positive clones were
selected and streaked for isolation. The clones were screened by PCR and DNA from
selected clones was isolated and sequenced with an upstream primer (pHT-seq primer: 5'GAATGATGTAAGCGTG-3') to confirm the orientation of the gene insert. Once the
gene sequence was confirmed, a clone was used to prepare a large-scale plasmid DNA
preparation (Qiagen). For constructing pHT01-Mel (mellitin) vector, the melittin gene
was amplified from pRr-Mel DNA vector using the forward (MelATG) and reverse (T3)
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primers. This gene fragment was ligated into Sma1 site of pHT01 to give pHT01-Mel
(Fig. 17) and XL-1 competant cells were transformed in SMMP medium using the ligated

Figure 17. Schematic representation
of pHT01-Mel expression vectors.
The melittin gene was cloned
downstream of the Pgrac promoter.

DNA. We initially screened 18 carbenicillin resistant clones (C1-C18) for the gene insert.
Among these clones, 3 clones (C3, C15 and C18) showed a specific DNA band by PCR
using HT and T3 primer. The plasmid DNA was prepared from these three clones.
Sequencing confirmed that C-15 and C-18 had the gene in the correct orientation in the
plasmid. The transformed clones were screened by PCR and DNA from selected clones
were isolated and sequenced with upstream primer (pHT-seqprimer 5'-GAATGATGTAAGCGTG-3') to confirm the orientation of the gene insert.
Bacillus subtilis protoplast preparation
Overnight culture of B. subtilis (1012 or 168) in LB were inoculated in 200 ml
Penessay broth and grown at 37ºC to midlog phase (O.D600 = 0.6). The cells were
centrifuged and resuspended in 20 ml SMMP containing 100 µg/ml lysozyme and
incubate with gentle shaking at 37ºC for 30 min. The cells were centrifuged, washed and
re-suspended in 10 ml cold SMMP. The protoplasts were aliquoted as 500 μl into
cryotubes and stored at -80°C until used.
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Bacillus subtilis protoplast transformation
For each transformation, a 500μl protoplast preparation was mixed with 5 μg of
plasmid DNA in a 15 ml tube. 1.5 ml of 40% polyethylene glycol was immediately added
and incubated for 2 minutes at room temperature. Protoplasts were diluted with 5 ml
SMMP and harvested by gentle centrifugation and removal of supernatant. After addition
of 500 μl SMMP cells were incubated overnight at 37 °C with gentle shaking. Then 50 to
200 μl cells were added to a prewarmed plate of LB containing the chloramphenicol and
incubated overnight at 37 °C. Controls without DNA or with empty plasmid (pHT01)
without insert were also prepared.
GFP and melittin protein induction studies
A single colony was selected from a freshly streaked LB-chloramphenicol
(transgenic B.subtilis pHT01-GFP clone or transgenic B.subtilis pHT01-Mel clone) and
put into 2 ml of LB- chloramphenicol broth for 16h. 500 µl of this culture was used as
inoculum to a 250 ml LBCmR broth and allowed to grow until the O.D600 reaches 0.4-0.5.
The culture was then induced with 1mM IPTG for various time periods. Uninduced cells
were used as the negative control. The induced cells at different time intervals were
centrifuged at 3000 g for 15 min. The cells were placed in lysis buffer (100 mM Tris-Cl,
500 mM NaCl, 0.5 M EDTA, 0.1% Triton X-100, 0.1% Tween-20, 8% glycerol, 250 mM
urea, 5 mM β-2 mercaptoethanol, 100 µg ml -1 PMSF, 1 µg ml -1 protease inhibitor
cocktail, 50 µg ml -1 lysozyme). The protein extracts from transgenic clones were
dialyzed overnight against 25 mM Tris-HCl (pH 7.2) with a 2 KDa (melittin extract) or
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10 kDa (GFP extract) Slide-A-lyzer (Pierce Biotechnology Inc., Rockford, IL, USA) at
4°C.
Western blot for GFP expression in transgenic Bacillus subtilis
One hundred µg of total protein, as determined by Bradford assay (BioRad,
QuickBradford kit, Hercules, CA, USA), were mixed with Lane Marker Reducing
Sample Buffer (Pierce Biotechnology Inc, Rockford, IL) and heated for 5 minutes in
80°C. The sample was electrophoresed on a 10% SDS-PAGE gel and transferred to a
PVDF membrane (BioRad, Hercules, CA, USA). The blot was blocked with 5% BSA in
tris buffered saline containing 1% tween-20 (TBST) for 1 hour, and washed three times
with TBST. It was then probed with a mouse anti-GFP antibody (Sigma-Aldrich) for 1
hour and washed three times with TBST, then probed with alkaline phosphatase-linked
goat anti-mouse antibody (Sigma Aldrich) at a dilution of 1:5000 and developed using an
alkaline phosphatase immunoblot detection system (Chemicon Inc, Billerica, MA, USA).
Growth characteristics and plasmid stability studies of the transgenic B.subtilis
strains
A single colony was selected from a freshly streaked LB (wild type B. subtilis
1012) or LB-chloramphenicol (transgenic B. subitlis-pHT01-Mel) plate to LB or LBchloramphenicol broth. The O.D600 values were determined at progressive time intervals
to track the growth curve of the wildtype and transgenic strain. The plasmid stability
studies were conducted as a modified protocol of Fleming et al. (1988). Briefly, LB was
inoculated from a single chloramphenicol-resistant colony. The culture was grown to an
O.D600 of 0.3-0.4 and then an aliquot of culture was serially diluted and plated in LB or
LB-chloramphenicol agar. After 24 h incubation, the colonies were counted. Another
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colony from LB-chloramphenicol agar was taken and inoculated into LB medium and
allowed to grow to an O.D600 of 0.2-0.3. This process was repeated daily for 7 days. The
number of colonies growing on the LB-chloramphenicol and on the LB was determined.
Western Blot for melittin expression in transgenic Bacillus subtilis
The samples were mixed with tricine sample buffer (Bio-Rad, Hercules, CA,
catalog # 161-0739) and boiled to at 80°C for 5 min. Equal amounts of protein as
determined by Bradford assays were separated on 4-16% Bis-Tris (NuPage
catalog#NP0322BOX) or 4-16% Tricine gels and transferred to 0.2 µm nitrocellulose
membrane (Bio-Rad, Hercules, CA, USA). Polypeptide marker (Biomarker) and melittin
control (2µl – 10 µM) was run simultaneously in separate lanes. The blot was blocked
with 5% BSA in TBST for 1 hour, and washed three times with TBST before adding
rabbit anti-melittin antiserum (Biosynthesis Inc., Lewisville, TX) at 1: 2000 and
incubated overnight at 4°C. The blot was then washed thrice, probed with an alkaline
phosphatase-linked goat anti-rabbit IgG antibody (Sigma-Aldrich) at a dilution of 1:4000
and developed using an ECL chemiluminescent detection system (Chemicon Inc,
Billerica, MA, USA).
ELISA for melittin detection
Purified B. subtilis bacterial extracts were diluted to 500µl in a carbonate buffer
(pH 9.5), and 1 µg total protein was incubated per well of a polystyrene 96-well plate
(high-binding capacity, Poly-Sorb, NuncTM) at 37°C for 90 min. After three washes in
TBST, the wells were further blocked with 2.5% BSA for 1 h at room temperature. The
wells were washed as before, and 100 µl of a 1:500 dilution of rabbit anti-melittin
antiserum was added (Biosynthesis Inc., Lewisville, TX) followed by incubation at 4°C
83

overnight. The wells were washed, and 100 µl of a 1:2500 dilution of anti-rabbit IgG
conjugated to horseradish peroxidase (Sigma-Aldrich, MO) was added. After a final set
of three washes, 100 µl of tetramethylbenzidine peroxidase substrate (BioRad, Hercules,
CA, USA) was added to each well and allowed to react for 10 min to develop color.
Color development was stopped with 100 µl 1µM H2SO4 per well and the absorbance
was read on ELISA plate reader (Molecular Devices, SupectraMAX 250, Sunnyvale, CA,
USA) at 450 nm. The background signal from B.subtilis control extract was subtracted
from samples. The melittin concentration in the extracts was estimated based on a
standard curve generated with synthetic pure melittin (Biosynthesis Inc., Lewisville, TX)
spiked into Bacillus subtilis extracts.
Statistical analyses
The means of the ELISA data from uninduced control and 2h-induced sample
were subjected to Students t test, and a p≤ 0.05 was considered significant. A statistical
software GraphPad Prism was used (GraphPad Software, Inc., San Diego, CA) to
perform this analysis.
RESULTS AND DISCUSSION
GFP expression by pHT01-GFP transformed B. subtilis strains
We selected pHT01 vector for expressing recombinant protein in B. subtilis.
pHT01 is an inducible vector which contains B.subtilis origin of replication. The
promoter, Pgrac, drives protein production with CmR as selection marker (Nguyen et al.,
2005). Although previous studies have shown that pHT01 can attain high recombinant
protein expression in B. subtilis (Phan et al., 2006), we wanted to confirm this. To that
end, we cloned the GFP gene downstream of the promoter to create pHT01-GFP and
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transformed two strains of B.subtilis (1012 and 168). We initially confirmed the GFP
expression in transgenic B.subtilis pHT01-GFP via fluorescence microscopy. Cells
induced with IPTG were glowing in fluorescent light from 30 min (Fig. 18B) post
induction, whereas no glowing cells were observed in uninduced sample (Fig. 18A).
B

A

Figure 18. GFP expression in B. subtilis 1012 transformed with pHT01-GFP. A)
Uninduced control B) Induced with IPTG 1 h.

We then biochemically demonstrated GFP expression via Western Blot. B.
subtilis 1012 transformed with pHT01-GFP showed protein expression from 0.5 to 3 h,
whereas no GFP expression was observed in the uninduced samples (Fig. 19). To
determine whether there is strain-specific difference in recombinant protein expression,
we also tested the GFP expression in B.subtilis strain 168. The same expression trend as
in B.subtilis 1012 was seen with B.subtilis 168 transformed with pHT01-GFP (data not
shown). These studies confirmed that pHT01 can effectively express recombinant
proteins in several B.subtilis strains.
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Figure 19. Western Blot showing GFP expression in B subtilis 1012 transformed
with pHT01-GFP. B.subtilis induced with IPTG for 3 hr (lane 1), 2 hr (lane 2), 1 hr (lane
3) and 0.5 hr (lane 4). Lane 5 is uninduced control; lane 6 is the protein marker.

Cloning melittin gene into pHT01 and molecular transformation of Bacillus subtilis
We cloned melittin gene upstream the promoter and confirmed the sequence and
orientation of the insert via PCR and sequencing. We then transformed B.subtilis 1012
and B.subtilis 168 with pHT01 (empty vector) and pHT01-Mel plasmid. The
transformation efficiency was low with ~ 15-20 CFU/5µg of plasmid DNA used. DNA
was purified from selected clones and subjected to PCR for confirming the presence of
melittin gene insert. PCR using specific primers showed DNA bands from both B.subtilis
168 and B.subtilis 1012 transformed with pHT01-Mel (Fig. 20) which was similar in size
compared to the positive control, pHT01-Mel plasmid. No PCR amplification was
observed in the negative control.
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Figure 20. Detection of the melittin gene in B subtilis transformed with pHT01-Mel by
PCR. 100bp DNA marker (lane 1); B.subtilis 1012 pHT01-Mel (lane 2); B.subtilis 168
pHT01-Mel (lane 3); pHT01-Mel DNA (lane 4, + control); B.subtilis-pHT01- (lane 5,control); PCR-Blank (lane 6, no DNA); pHT01-Mel DNA, colony (lane 7, + control).

Growth characteristics and plasmid stability of the transgenic strains
The growth of B.subtilis 1012-pHT01-Mel was similar to that of the nontransformed clone. Similarly, B.subtilis 168-pHT01-Mel showed similar growth as
B.subtilis 168 without the plasmid (Fig. 21A and B). This suggests that the
transformation using pHT-based plasmids did not alter the growth properties of
B.subtilis. The pHT01-Mel plasmid was stable in the B. subtilis 1012 clones for 7 d (Fig.
22) consistent with previous studies in B.subtilis (Phan et al., 2006).
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Figure 21. Growth characteristics of wildtype and transgenic B. subtilis lines.
A)Transgenic and non-transformed (WT) B.subtilis strain 1012 B) Transgenic and nontransformed (WT) B.subtilis strain 168.
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Figure 22. Plasmid stability of
transgenic B. subtilis-pHT01-Mel
clone. Colony forming units
(CFU) were measured over the
course of 7 days in the presence
(which requires the pHT01
plasmid) or absence of
chloramphenicol.

Standardization of Western Blot
Extract of wild type B. subtilis 1012 was spiked with different concentrations of
synthetic melittin to determine the detection limit of our assay. We used two different gel
systems to resolve the peptides; Tricine gel system (Novax) and Bis-Tris (Novagen). We
blotted the gel into 0.2 micron nitrocellulose membranes and probed with anti-melittin
serum (1:2000 dilution). The tricine gel clear melittin-specific band in B. subtilis extract
spiked with as low as 44 ng melittin (Fig. 23). High molecular weight bands (16KDa)

Figure 23. Detection limit by Western blot of melittin spiked after extract preparation.
Melittin spiked B.subtilis Ext- 43.8 ng (lane 1); 87.5 ng (lane 2); 175 ng (lane 3); 350 ng
(lane 4); 700 ng (lane 5); 1400 ng (lane 6); 2800 ng (lane 7); positive control synthetic
melittin in PBS (lane 8); polypeptide marker (lane 9).
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were observed in the blot suggesting cross reactivity of antiserum with the B.subtilis
extract. The bis-tris gel system and subsequent blot gave melittin specific band with 175
ng melittin (not shown). There was more background in bis-tris based blot, hence all our
subsequent experiments we used only tricine gel system. We then asked whether the
extract preparation and dialysis process reduced the melittin signal by spiking the
B.subtilis extract during lysis step (dring the first vortexing after adding the lysis buffer)
with increasing concentration of melittin. Our Western Blot showed specific bands at
minimum of 350 ng mellittin as compared to 44 ng when melittin was added after
dialysis, indicating that there was an 80% loss due to dialysis (Fig. 24).

Figure 24. Detection limit by Western blot of melittin spiked before dialysis of extract
preparation. No sample- loading buffer only (lane 1); Melittin spiked B.subtilis Ext- 43.8
ng (lane 2); 87.5 ng (lane 3); 175 ng (lane 4); 350 ng (lane 5); 700 ng (lane 6); 1400 ng
(lane 7); 2800 ng (lane 8); positive control synthetic melittin in PBS (lane 9); polypeptide
marker (lane 10).

Melittin detection using Western Blot and ELISA
We conducted a series of melittin induction studies using two transgenic B.subtilis
strains (B.subtilis168- and B.subtilis 1012) carrying pHT01-Mel plasmid. We varied the
induction temperature or induction time in these trials. The first three studies (Study1-3),
we used B.subtilis168-pHT01-Mel and the next four studies, we used B.subtilis 101290

pHT01-Mel (Table 7). None of the protein extracts prepared from these studies showed
any melittin expression in our Western Blot assay (Fig. 25). We also failed to detect
melittin expression in insoluble fractions and media supernatant from induced samples
(not shown). The Western Blot from various induction studies suggested that either the
clones are not expressing melittin or it was below the detection limit (300-400ng).
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Figure 25. Western blot to detect melittin (Study 4). No melittin specific band was
observed from the induced samples. pHT-Mel 3 h Ind (lane 1); pHT-Mel 2h Ind (lane 2);
pHT-Mel 1.0 h Ind (lane 3); pHT-Mel Uninduced (lane 4); Syn Mel- positive Control
(lane 5); Polypeptide marker (lane 6).
In order to have a more sensitive assay for melittin, we employed ELISA and
spiked melittin into B.subtilis extracts for a standard curve. The standard curve gave a
dose-dependent melittin specific signal range of 0.03 to 0.5 μM (Fig. 26A). The extracts
from IPTG induced B. subtilis 168-pHT01-Mel clones showed a 12-fold increase in
melittin signal in 2 h induced samples compared to uninduced control samples (Fig.
26B). A similar trend of melittin expression was observed from the induced extracts from
B. subtilis-1012-pHT01-Mel clones (not shown). An estimate of melittin expression in
transgenic B.subtilis were calculated using the melittin-spiked B.subiltis extract standard
curve and was in the range of 200-400 ng per 10 million cells (2 - 4 x 10-5ng/cell).
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Studies have shown that transgenic strains of B.subtilis can produce 5-8µg protease and
2-3µg single-chain antibody from 10 million cells (Schumann, 2007). Compared to this
efficiency, the level of recombinant melittin production in the present study was low.

Figure 26. ELISA to detect melittin production from transgenic B. subtilis 168-pHT01Mel. A) Standard curve of melittin spiked (0.03-0.50 µM) in PBS or B.subtilis 168
extract B) Melittin specific signal from 2 h induced samples compared to uninduced
control samples. The asterisk represents significant difference in the means (P <0.05).

There might be several reasons for this low-level melittin expression. The stability
of short peptides in a cellular protease-rich environment might be low due to peptide
degradation. The peptides might aggregate into high molecular structures in the cellular
environment. Further, melittin could interact with intracellular targets, reducing
expression. Although our previous studies have shown that B. subtilis is resistant to
exogenous peptides, there might be deleterious effects to the host cell expressing the
peptides. We also inserted a methionine codon to initiate translation, which was
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Table 7. Summary of melittin induction studies using B.subtilis 168-pHT01-Mel and B.subtilis 1012-pHT01-Mel1
Study #

B.subtilis

Growth

Induction

Induction time

strain

temperature

temperature

Study 1

168

30ºC

25ºC

1h, 2h, 3h

Study 2

168

30ºC

30ºC

Study 3

168

30ºC

Study 4

1012

Study 5

Lysis method

Melittin detection by method
WB

ELISA

CLB2+vortex

-

+

1h, 2h, 3h

CLB+vortex

-

+

25ºC

30m, 45m, 90m

CLB+vortex

-

nd

30ºC

25ºC

1h, 2h, 3h

CLB+vortex

-

+

1012

30ºC

30ºC

1h, 2h, 3h

CLB+vortex

-

+

Study 6

1012

30ºC

25ºC

30m, 45m, 90m

CLB+vortex

-

nd

Study 7

1012

30ºC

25ºC

1h, 2h, 3h

CLB+sonication

-

+

1

Abbreviations: CLB, complex lysis buffer; NB40, NB40 lysis buffer; WB-, not detected by Western blot;
ELISA+, low level detection by enzyme linked immunosorbent assay; nd, not done
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not part of the native peptide, and this might have contributed to the low expression.
For functional anti-vibrio activity for paratransgenic approaches it would be ideal
to increase the melittin expression at least an order of magnitude in the range of 1-2 x10-4
ng/cell. Several strategies for accomplishing this are proposed in Chapter 6.
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CHAPTER 6
GENERAL SUMMARY AND FUTURE DIRECTIONS
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GENERAL SUMMARY
Although infectious disease is a major threat in shrimp mariculture throughout the
world, there are not many sustainable methods available to combat these disease
problems (Hill, 2005). However, shrimp aquaculture is the fastest growing food sector
globally and holds great promise for closing the nutritional gap for much of the world‟s
population (Smith et al., 2010). The need to devise novel and sustainable methods against
various infectious agents is pressing as traditional methods such as antibiotics are banned
and other methods are not effective. We seek to develop a practical and viable infectious
disease control system for shrimp producers based on a novel approach called
paratransgenesis. The main aim of this dissertation is to develop a marine paratransagenic
approach, a disease control method initially developed to control vector-borne-diseases,
as a way to control shrimp diseases. In the classical paratransgenic strategy, commensal
or symbiotic bacteria found at mucosal sites of pathogen transmission are isolated and
genetically altered to elaborate immune peptides or engineered single-chain antibody
fragments (scFv) that neutralize infectious agents. The transgenic bacteria are then
delivered back to mucosal sites where disease transmission occurs. In large-scale shrimp
rearing, larval stages are fed with Artemia -an aquatic crustacean feed organism to boost
nutrition and improve survival in hatcheries. Artemia, which are reared separately, are fed
with microalgae and other probiotic bacteria. Artemia is a nearly ideal feed organism:
economical, hardy, and readily available worldwide. As with classical paratransgenesis,
there are four elements associated with the shrimp culture system; the Artemia, which is
the arthropod intermediate, the microalgae feed organisms, the disease-causing bacteria

96

such as Vibrio, Aeromonas etc, and finally the host shrimp, which succumbs to the
disease.
To apply this paratransgenic strategy to diseases of farmed shrimp, we proposed a
modified paratransgenic approach that involves organisms used as feed for marine
animals (Durvasula et al., 2006; Durvasula et al., 2009). We hypothesized that Artemia
can be used as an effective delivery for recombinant proteins that impart passive
immunity to shrimp against a variety of infectious pathogens.
First, we wanted to study the accumulation and retention of recombinant proteins
in Artemia gut for a specific period of time for optimizing paratransgenic disease control
in shrimp aquaculture. Transgenic Escherichia coli expressing fluorescent marker
proteins and the transgenic cyanobacterium Synechococcus bacillarus expressing a
functional murine single-chain antibody, DB3, were fed to Artemia. Stable expression
and retention of several marker molecules (e.g. GFP, DS Red and DB3) up to 10 h after
feeding with E. coli were evident within the gut of Artemia. Engineered strains of S.
bacillarus expressing DB3 accumulated within the gut of Artemia, with detectable
antibody activity for 8-10 h of feeding via ELISA, coincident with the time period of
highest density of transgenic S. bacillarus in the Artemia gut, suggesting that
recombinant proteins can be delivered effectively to nauplii of Artemia and retain their
biological activity (Subhadra et al., 2010). Co-delivery of two recombinant proteins
simultaneously in the gut of Artemia was also demonstrated. During these first sets of
studies for developing a marine paratransgenic approach, we have demonstrated delivery,
retention and biological activity of recombinant proteins in the gut of Artemia.
Furthermore, co-expression of multiple markers in the gut of Artemia confirms that
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paratransgenic manipulation of these animals for delivery of a battery of molecules with
activity against pathogens is possible. This method of delivering recombinant proteinproducing microbes via Artemia to shrimp larval stages utilizes the natural feeding
behaviors of both Artemia and farmed shrimp and may permit bioamplification of the
functional antibodies through the food chain (Durvasula et al., 2009). This strategy could
be quite significant in settings of drug-resistant pathogens where concurrent delivery of
molecules that act at different target sites of the pathogen would slow the emergence of
resistant species. Expression of molecules which target infections agents of mariculture in
shrimp via commonly deployed feed organisms such as Artemia could potentially offer
powerful new tools in the ongoing global effort to increase food supply.
To begin to develop paratransgenic shrimp, we studied the delivery of transgenic
proteins to the shrimp, Litopenaeus vannmei via direct feeding of transgenic bacteria or
via feeding through transgenic-bacteria engorged Artemia. We conducted three shrimp
feeding protocols. Trial 1 was designed to evaluate the accumulation of an engineered
antibody in the gut of L. vannamei consisted of an 18 day active feeding phase followed
by 12 d wash-out phase. In trial 2 and 3, which were designed to determine the dynamics
of recombinant GFP within the gut of paratransgenic L. vannamei fed with GFP
expressing bacteria engorged Artemia or fed directly with GFP-expressing EcN bacteria.
Results from the feeding protocols showed that shrimp gut fed with paratransgeinc
Artemia and transgenic bacteria showed an increase in the recombinant protein during the
active feeding phase and a decrease in recombinant protein during the wash-out phase.
The biotransfer of recombinant GFP via Artemia to shrimp caused accumulation of 1015% more protein in the gut of shrimp fed 20 or 40 Artemia per shrimp per day than via
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direct feeding of transgenic bacteria (106 CFUml-1). Through these studies we
demonstrated that recombinant functional proteins can be delivered to shrimp via
Artemia in a paratransgenic approach. Therefore, bioaccumulation of anti-infectious
protein molecules such as antibodies, cationic peptides, and antivirals to shrimp via a
paratransgenic approach holds promise for sustainable disease –mitigation in shrimp
mariculture.
We selected Vibriosis as the target disease for proof of concept studies. Vibriosis
is one of the most devastating diseases caused by at least 14 species of Vibrio (Brock and
Lightner, 1990). Highly virulent strains such as Vibrio harveyi, V. campbellii, V.
penaeicida, and V. nigripulchritudo can cause up to 90% mortality within a day of
infection in Penaeus monodon, P. japonicus and L. vannamei (Lavilla-Pitago et al.,
1998). The lack of an adaptive immune response limits the use of Vibrio-specific
vaccination strategies in shrimp (Hill, 2005). Use of antibiotics in aquaculture is banned
in many countries due to emergence of drug-resistant microbes (FAO-WHO, 2006).
The first task was to screen antivibriocidal molecules, which can be used in the
marine paratransgenic approach. Cationic peptides such as cecropin, apidaecin, magainin
and melittin, which are part of natural innate immunity (Zasloff, 2002), could serve as
effector molecules in a marine paratransgenic strategy to control Vibriosis. These
peptides neutralize a variety of Gram- negative bacteria at submicromolar to low
micromolar concentrations, including some antibiotic resistant strains (Stark et al., 2002).
This study examines the in vitro activity of 5 different antimicrobial peptides against
different Vibrio spp., probiotic bacteria and algae, the last two being potential candidates
to express these molecules in paratransgenic control. We also studied the evolution of
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resistance against single cationic peptide treatments and report here that a combination of
cationic peptides can avoid emergence of resistance in V. harveyi, V. penaeicida, and V.
campbellii, the three most important shellfish pathogens.
Moricin was the most potent antimicrobial agent against Vibrio spp. with a
minimum bactericidal concentration (MBC) in the 0.04-0.31 µM range. Cecropin and
melittin killed Vibrios in the MBC range of 0.02-17.5 and 2.5-10.0 µM, respectively.
Probiotic bacteria and algal feed organisms (e.g. Bacillus subtilis, Brevibacterium linens,
Dunaliella salina and Synechococcus bacillarus) displayed high levels of resistance
toward cecropin and melittin suggesting that they would be suitable for a paratransgenic
approach to Vibriosis in shrimp. A mixture of 0.01 µM cecropin and 0.1 µM melittin was
bactericidal against Vibrio spp. demonstrating synergistic activity. A mixture of 0.01 µM
cecropin and 0.01 µM melittin prevented evolution of bacterial resistance, suggesting that
simultaneous expression of these peptides could offer new tools in a paratransgenic
approach to Vibriosis in shrimp aquaculture. To test the protective efficacy of these
peptides in vivo, we conducted Vibrio challenge trials on Artemia. A mixture of cecropin
and melittin at a concentration as low as 1 µM partially protected Artemia against the
highly pathogenic Vibrio campbellii CAIM 372. Toxicity of the peptides toward Artemia
was not observed, even at concentrations as high as 5 µM. The protective effect of the
peptides appears to be due to low colonization of Vibrio as indicated by the significantly
lower V. campbellii load in Artemia samples treated with peptides during the initial 2-4 h
after bacterial challenge. In summary, this study indicates that melittin and cecropin, two
naturally occurring antimicrobial peptides, have potential applications as anti-Vibrio
agents in paratransgenic strategy for control of pathogenic Vibrios. Both agents exhibit
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selective toxicity toward diverse strains of Vibrios with minimal effect on feed bacteria
and algae. Furthermore, when delivered concurrently, they exhibit marked synergistic
activity toward Vibrio spp. and appear to slow evolution of target bacterial resistance.
Paratrangenic systems make use of transgenic host bacteria that expresses antiinfectious molecules. Since melittin and magainin have antibacterial activity against
pathogenic vibrios and no activity against B. subtilis, we cloned melittin and magainin
gene into pHT01, a B. subtilis-specific inducible expression vector, for the production of
melittin and magainin. The growth patterns of transgenic strains were similar to the wild
type strain. The pHT-based plasmids were stable in B. subtilis with neglible plasmid loss
during 7 d study without antibiotic selection. Our ELISA data showed that transgenic B.
subtilis pHT-Mel exhibited low but detectable levels of melittin expression. However, in
vitro and in vivo anti-vibrio studies indicated that this level of recombinant peptide
expression was insufficient to cause detectable anti-bacterial activity.
FUTURE RESEARCH DIRECTIONS
The following are key research areas for further developing marine paratransgenic
system as an environmentally sustainable disease mitigation strategy in the aquaculture
sector.
1. Optimization of melittin expression in Bacillus subtilis
There might be several reasons for the low level expression of melittin. The
stability of peptides such as melittin in a cellular protease-rich environment might be low
(Jenssen et al., 2006). The cationic peptides such as melittin can also aggregate into high
molecular structure in cellular environment (Raghuraman and Chattopadhyay, 2007).
Further, melittin has some intracellular targets (e.g. it can affect intracellular signaling,
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calcium channels, cell-wall synthesis, and ribosome stoichiometry (Mix et al., 1984;
Kataoka et al., 1989)), which might have negatively interacted with the protein synthesis
machinery and reduced the expression (Jenssen et al., 2006). Although we showed that B.
subtilis is resistant to exogenous antimicrobial peptides (Chapter 4), there might be
deleterious effects to the host if the peptide is expressed intracellularly. We also inserted
a translation start codon for methionine amino acid upstream of the melittin gene. The
change in the structural nature of the peptide due to this addition might have interfered
with the level of melittin expression.
Various strategies can be devised to optimize the expression of AMP in B.subtilis.
Inserting an inactive pre-pro gene segment upstream of coding region of melittin gene
may enhance the expression of AMP. A similar strategy naturally occurs with certain
B.subtilis strains for the production of subtilin. Subtilin is a short cationic peptide of 3.4
kDa and has broad-spectrum bactericidal activity against both Gram positive and Gram
negative bacteria. The subtilin is expressed as a propeptide which is secreted outside the
cell. Multiple of proteins are associated with the production, post translational
modification and secretion of subtilin (Fig. 27). The inactive pro-subtilin secreted outside
the cells is cleaved to active subtilin by nonspecific serine proteases (Abriouel et al.,
2001).
Similar to this natural mechanism, melittin can also be expressed as an inactive
propeptide with a signal sequence to affect secretion outside the cell. Such a pro-peptide
can be cleaved to its active form using the dipeptidases in Artemia or shrimp digestive
system (Fig. 28). A comparable approach using another AMP, bovine lactoferricin
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(LFB), has been recently described by Li et al. (2009) for the control of Vibrio
parahaemolyticus infection in fish.

Figure 27. Mechanisms of natural expression of AMP in B.subtilis. Subtilin is expressed
as a propeptide in the cell prior to secretion. Multiple proteins are associated with the
production, post-translational modification and secretion of subtilin. The inactive
secreted pro-subtilin is cleaved to active subtilin by nonspecific serine proteases
(Abriouel et al., 2001).

Figure 28. Possible strategy to express melittin in B.subtilis for paratransgenesis.
Melittin can be expressed as a pro-peptide by cloning a signal peptide gene upstream of
the melittin gene. The inactive pre-melittin could be cleaved by shrimp gut proteases to
release active melittin.

They transformed Nannochloropsis oculata, a larval feed alga, to express LFB as an
inactive propeptide. The propeptide was designed in such as way that the fish digestive
enzymes cleaved off the active peptide. The medaka fish (Oryzias latipes) were fed with
the transgenic algae followed by Vibrio parahaemolyticus infection challenge. For fish
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fed transgenic algae, the average survival rate after a 24-h period of infection was much
higher than that of medaka fed with wild-type algae suggesting that the LFB-containing
transgenic microalgae had bactericidal action against V. parahaemolyticus in medaka fish
digestive tract.
Recently, for the recombinant extracellular expression of cecropin AD, a chimeric
AMP which has the first 11 amino acid residues from cecropin A and the last 26 residues
from cecropin D, was achieved in B. subtilis (Chen et al., 2009). They fused the cecropin
AD gene with a small ubiquitin-like modifier gene (SUMO) and a signal peptide, SacB,
and a B.subtilis expression system was constructed by the introduction of an operon
including an isopropyl-beta-D-thiogalactopyranoside (IPTG)-inducible Spac promoter, a
signal peptide of amyQ, and the SUMO protease gene (Fig. 29). High level recombinant
cecropin AD production was obtained using this expression system (30.6 mg of
recombinant cecropin AD was purified from one liter of culture supernatant).

Figure 29. Recombinant cecropin AD expression in B.subtilis. B.subtilis was transformed
with plasmid to express cecropin AD as a fusion protein with SUMO protein (cecropin
AD+SUMO protein). The signal peptide in the plasmid, SacB, promotes the extracellular
secretion of cecropin AD+Sumo protein. The plasmid also expresses and extracellularly
secretes SUMO protease, which specifically cleaves SUMO protein from the fusion
protein to release the active cecropin AD (Chen et al., 2009).
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The SUMO (small ubiquitnin-like modifier) protein component of the protein has
a chaperone characteristic, which enhanced protein expression, enhanced stability,
reduced proteolytic action, and enhanced solubility/folding. A similar approach for the
melittin expression can also be devised. Plasmid can be designed to expression melittin
fused to SUMO protein with concurrent expression of SUMO protease from the same
plasmid. This will give melittin high stability and the peptide can be cleaved via the
expressed SUMO protease into its active form as depicted in Fig. 30.
2. Transformation of algal species to express anti-infectious agents
Algal strains such as Dunaliella salina, Phaeodactylum tricornutum,
Nannochloropsis are extensively used in aquaculture larval nutrition. These strains are
ideal because of the high nutritious components such as long chain fatty acids and
vitamin contents. Genetic transformations of these strains to express recombinant
proteins are also described (Apt et al., 1996; Mayfield et al., 2003).

Figure 30. Possible strategy to express melittin in B.subtilis for paratransgenesis.
B.subtilis can be transformed with plasmid to express melittin as a fusion protein with
SUMO protein (melittin+SUMO protein). The plasmid also expresses and extracellularly
secretes SUMO protease, which specifically cleaves SUMO protein from the fusion
protein to release the active melittin.
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Moreover, our studies have found that algal species such as Dunaliella and
Synechococcus are more resistant to AMPs. As algal species are ideal larval feed, another
future direction in marine paratransgenic approach is the development of strains of algae
which express anti-infectous molecules against marine pathogenic virusus and bacteria.
3. Developing specific anti-infectious molecules in a paratrangenic approach
Anti-VP28 single chain antibody, a White spot syndrome virus viral entryblocking molecule, can be used against WSSV. Similary, PmAV is antiviral protein
expressed in WSSV-resistant shrimp, can also be used for paratransgenic approach.
Engineering single chain antibodies with high neutralizing capacity against marine
infectious virus (WSSV) and bacteria (Vibrio spp, Aeromonas spp) may have
considerable value. These molecules are preferred over AMPs for the following reasons:
1) They are larger proteins: Antibodies are high molecular weight proteins and
chemically more stable. The expression of these molecules for functional purposes in
shrimp gut may undergo less degradation compared to small peptide molecules.
2) There should be less host cellular effects: The expression of antimicrobial peptides in
host bacteria for paratransgenic application may interfere with the physiology of host
bacteria. However, target-specific antibodies should not have deleterious effects on host
bacteria.
3) They target specific pathogens: Specific antibodies can be engineered for pathogens so
there should be no non-specific effect on other bacterial flora in the shrimp gut.
4) There is less probability of antibiotic resistance: Use of antimicrobial peptides poses
the risk of emergence of peptide-resistant bacteria. The use of target-specific antibodies
against an essential bacterial epitope will not have this negative implication.
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Similarly, broad-spectrum antiviral proteins such as cyanovirin (Bewley et al.,
1998), griffithsin (Mori et al., 2005), and PmAV (Luo et al., 2003) can also be explored
for controlling viral diseases of mariculture via marine paratrangenic approach.
4. Expression of quorum-sensing molecules in paratransgenic host bacteria
Quorum-sensing blocking molecules are a new strategy for disease control against
infectious diseases. The term "quorum sensing" describes the ability of a microorganism
to perceive and respond to microbial population density, usually relying on the
production and subsequent response to diffusible signal molecules (Miller and Bassler,
2001). A significant number of gram-negative bacteria produce acylated homoserine
lactones as signal molecules that function in quorum sensing. This is particulary
important in controlling Vibros because most of the Vibrio species rely on quorum
sensing molecules for growth, proliferation and pathogenicity (Miller and Bassler, 2001).
Research groups have already proposed the scope of disruption of quorum sensing
against Vibrio harveyi infection in aquaculture (Defoirdt et al., 2007; Liu et al., 2010).
Recently, Duan and March (2010) investigated the possibility of using commensal
bacteria as signal mediators for inhibiting cholera. Their study found that pretreatment of
mice for 8 hours with Escherichia coli Nissle expressing cholera autoinducer 1, a quorum
sensing blocking molecule, significantly increased mouse survival from ingestion of V.
cholera. Similar to this, engineering algae and bacteria to express quorum-sensing
blocking molecules against marine pathogenic vibrios holds promise for sustainable and
specific disease control strategies in mariculture.
In conclusion, the dissertation research has demonstrated the feasibility of a
paratransgenic approach for delivering proteins to Artemia and shrimp for disease
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control. Further laboratory-based studies for the refinement of this approach for various
bacterial and viral diseases are needed for the ultimate goal of farm-level applications.
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